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Immunomodulatory properties of flagellin in antigen presenting cells
Ildefonso Vicente-Suarez
ABSTRACT
Toll-like receptors (TLRs) expressed by cells of the immune system play a central role in
the generation of immune responses against pathogens. Following TLR ligation, both
pro-inflammatory and anti-inflammatory mediators are produced in order to elicit an
immune response that controls the microbial infection while limiting tissue damage.
Among these mediators, the proinflammatory cytokine IL-12 and the anti-inflammatory
cytokine IL-10 are known to play major roles. Here, we show that in vitro or in vivo
stimulation with flagellin, the TLR5 ligand, does not result in IL-10 production.
Furthermore flagellin inhibits IL-10 production by other specific TLR ligands at the
protein and mRNA levels while increasing IL-12p70 production. Several studies have
linked the activation of extracellular signal regulated kinases (ERKs) with IL-10
induction by TLRs. Our findings that LPS-induced ERK activation is significantly
decreased in flagellin-treated macrophages suggest that this pathway might play a role in
the inhibition of IL-10 production by flagellin. Flagellin-mediated IL-10 inhibition was
not observed in cells that do not express TLR5 supporting that this effect is TLR5dependent.
Flagellin used as an adjuvant is capable of priming antigen specific T cell responses in an
in vivo model of tolerance using high dose peptide. Furthermore, DCs differentiated in
tolerogenic conditions (tolerogenic-DCs) express higher levels of TLR5 mRNA than
xiii

standard BM-DCs and respond more vigorously to flagellin stimulation. Antigen
presentation by LPS-matured tolerogenic-DCs results in the differentiation of IL-10
producing T cells with a Tr1-like phenotype. On the contrary, antigen presentation by
tolerogenic-DCs that have been stimulated with flagellin results in the differentiation of a
typical Th1 response
This study provides a new insight of the role of flagellin recognition by TLR5 in shaping
the immune response elicited by flagellated microorganisms.

xiv

INTRODUCTION

T cell tolerance and antigen presenting cells
Bone marrow-derived antigen presenting cells (APCs) and in particular dendritic
cells (DCs) play a central role in the generation of antigen-specific T-cell responses (1).
However, these same cells are also required for the induction of T-cell tolerance (2). This
seemingly dual function of APCs was attributed initially to the existence of specific APC
subpopulation(s) that induce T-cell priming while other subpopulations induce T-cell
anergy (3-5). The demonstration that priming and tolerance can be induced by a single
APC subpopulation (6) led to the alternative explanation that the functional status of the
APC would be the major factor determining T-cell activation versus T-cell tolerance.
Antigen encounter in the presence of inflammatory mediators and/or microbial products
triggers the maturation of the APC to a functional status capable of priming T cell
responses (Figure 1A). In contrast, antigen capture by these same APCs in the absence of
inflammatory signals, or in the presence of inhibitory mediators, leads to the development
of antigen specific T-cell tolerance (Figure 1B) (2).
Dendritic cells (DCs), macrophages and B-cells are all bone marrow (BM)derived cells that express major histocompatibility complex class II (MHC II) as well as
costimulatory molecules and, as such, can potentially present antigens to the T-cells.
Although it is plausible that under particular conditions each subpopulation might induce
1

T-cell tolerance (7-12), several lines of evidence have pointed to the DCs as the
main cell type involved in the development of peripheral tolerance (13-16). Immature
DCs constantly migrate within tissues and secondary lymphoid organs (17). Under
steady-state conditions, immature DCs capture apoptotic bodies arising from cell
turnover and migrate to the draining lymph nodes where antigen presentation takes place.
Phagocytosis of apoptotic bodies does not cause DC maturation, and therefore antigen
presentation of tissue antigens phagocytosed by immature DCs might represent a
common mechanism of tolerance-induction to self antigens (17). Tumor growth
especially at early stages when the tissue architecture has not been yet disrupted does not
induce the release of inflammatory mediators. Therefore, it was proposed that uptake of
tumor antigens occurs in an identical manner as uptake of tissue self-antigens and the
same mechanisms that establish T-cell tolerance against self will also prevent the immune
response against tumors (18). In the mid 90’s, the demonstration by the Bogen’s and
Levitsky’s groups that antigen-specific CD4+ T-cells were rendered tolerant during tumor
growth in vivo provided the first experimental evidence supporting the tumor-induced
tolerance hypothesis (19-20).
Since then, several studies have confirmed that antigen specific CD4+ as well as
CD8+ T cell tolerance occurs during the progression of both hematologic and solid
tumors expressing model or true tumor antigens (21-28). Furthermore, data from our
laboratory and others have demonstrated that bone marrow (BM)-derived APCs are
required for the induction of tolerance to antigens expressed by tumor cells (21) (29).
These studies also provided evidence that the intrinsic antigen presenting capacity of
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tumor cells has little influence over T cell priming versus tolerance, a critical decision
that is regulated at the level of the APC.
Antigen presentation by immature DCs, self-antigens or tumor antigens alike,
induces a modest T cell proliferation but not polarization into T helper 1 (Th1) or Th2
subsets. Instead, after several rounds of cell division almost all the antigen specific Tcells are deleted. The remaining T cells are functionally anergic upon antigen
restimulation even when the antigen is administered with a strong adjuvant such as
Complete Freund Adjuvant (CFA) (30-31). Furthermore, antigen presentation by
immature DCs can also result in the development of regulatory T cells with the ability to
suppress effector responses by other T cells (32) (Figure 1B).
In the tumor bearing host, antigen encounter by DCs might occur not only in the
absence of inflammatory signals, but also in the presence of inhibitory factors such as
interleukin (IL)-10, transforming growth factor-beta (TGF-β) (33), phosphatidylserine
(PS) and prostaglandin E2 (PGE2) (34-36) that further suppress the APC’s function. In
this adverse environment, DCs acquire features as the production of IDO, and IL-10 that
result in strong suppression of immune responses (37) (38). IL-10 production by DCs
induces the differentiation of regulatory T cells that themselves produce high levels of
IL-10 and further suppress inflammatory responses (38). The goal of immunotherapy is
to disrupt this vicious cycle in order to elicit an effective immune response against the
tumor. Microbial products recognized by Toll-like receptors (TLRs) are considered the
strongest stimulus to induce APC maturation and as such, in this proposal we focus in the
better understanding of their inflammatory properties as a potential strategy to effectively
harness antitumor immune responses (39).
3

FIGURE 1. T cell priming versus tolerance is determined by the state of activation of
the APC
(A) In the course of an infection, microbial products are recognized by the APC through
TLRs. TLR stimulation results in APC maturation, a process that increases the levels of
costimulatory molecules and cytokine production. Antigen presentation by mature APCs
leads to efficient priming of naïve T cells that proliferate and differentiate into effector
cells. (B) Phagocytosis of self-antigens or tumor antigens in a non-inflammatory
environment does not cause APC maturation. Immature APCs display low levels of
costimulatory molecules and cytokine production. Antigen presentation by immature
APCs to naïve T cells results in transient proliferation followed by induction of anergic
and/or regulatory T-cells.
4

TLRs
The immune system has evolved to fight off microbial invasions that represent a
constant thread to any multicellular organism. The mammalian immune system is divided
in two broad categories, innate and acquired immunity. The acquired branch of immunity
is only present in vertebrates and is characterized by a specialized cell type known as
lymphocytes. There is two major lineages of lymphocytes called T (for thymus-derived)
and B (for bursa- or bone-marrow-derived). The attribute that makes lymphocytes
different from other cells of the immune system is the presence of antigen receptors in
their cellular surface. Engagement of these receptors results in clonal amplification,
cellular differentiation, and in B cells, production of antibodies with the same antigen
binding specificity. Somatic diversification of the antigen-receptor genes generates a vast
repertoire of cells, each of which expresses a different antigen receptor. This feature
provides the acquired immune system with the ability to recognize an unlimited array of
ligands. The T cell receptors (TCRs) bind peptide fragments presented by other cells
within cell-surface molecules encoded by the MHC class I and class II genes. Therefore,
T lymphocytes typically recognize antigens that have been partially digested by the
antigen-presenting cells, primarily dendritic cells. In contrast, the B cell receptor (BCR)
and antibodies recognize exposed determinants (epitopes) of intact molecules.
Innate immunity is ancient, characterized by the presence of phagocytic cells and
found in every organism studied. Innate immune cells express receptors that are present
on all cells of a given type and are not subject to rearrangement. These receptors
recognize microbial products that are not present in the host, and therefore discriminate
“non-infectious self” from “infectious non-self” (40). Microorganisms have the ability to
5

rapidly change under environmental pressure; consequently innate immune receptors
have evolved to target molecules essential for the microorganism survival and therefore
less susceptible to be altered. These molecules have been denominated pathogenassociated molecular patterns (PAMPs) (41) and the receptors that sense them, patternrecognition receptors (PRRs) (42). Toll-like receptors are the most studied family of
PRRs and received their name from the Drosophila receptor Toll (43), a receptor
involved in embryonic development but also in the defense against fungal infection (44).
The first indication that mammalian TLRs may function as pattern recognition receptors
came with the description of a human homologue of Drosophila Toll, now known as
TLR4 (45). So far 11 members of the TLR family have been identified based on the
homology in the cytoplasmic region that exists among all of them. The TLR intracellular
domain is homologous to the IL-1R domain and for that reason it has been named
Toll/IL-1R homology (TIR) domain. The TLR extracellular domains contain a varying
numbers of leucine-rich-repeat (LRR) motifs. These motifs form a horseshoe structure,
and it is thought that the concave surface of this structure is directly involved in the
recognition of PAMPs (46). The TLR family members identified so far and their ligands
are summarized in Table 1.

6

Microbial Components

Species

TLR/s

BACTERIA
LPS
Diacyl lipopeptides
Triacyl lipopeptides
LTA (Lipoteichoic acid)
PG (Peptidoglycan)
Porins
Lipoarabinomannan
Flagellin
CpG-DNA
Non-defined

Gram-negative bacteria
Mycoplasma
Bacteria and mycobacteria
Group B Streptococcus
Gram-positive bacteria
Neisseria
Mycobacteria
Flagellated bacteria
Bacteria and mycobacteria
Uropathogenic bacteria

TLR4
TLR6/ TLR2
TLR1/ TLR2
TLR6/ TLR2
TLR2
TLR2
TLR2
TLR5
TLR9
TLR11

FUNGUS
Zymosan
Phospholipomannan
Mannan
Glucuronoxylomannan

Saccharomyces cerevisiae
Candida albicans
Candida albicans
Cryptococcus neoformans

TLR6/ TLR2
TLR2
TLR4
TLR2 and TLR4

PARASITES
tGPI-mutin
Glycoinositolphospholipids
Hemozoin
Profilin-like molecule

Trypanosoma
Trypanosoma
Plasmodium
Toxoplasma gondii

TLR2
TLR4
TLR9
TLR11

VIRUSES
DNA
dsRNA
ssRNA
Envelope proteins
Hemagglutinin protein
Non-defined

Viruses
Viruses
RNA viruses
RSV,MMTV
Measles virus
HCMV,HSV1

TLR9
TLR3
TLR7 and TLR8
TLR4
TLR2
TLR2

Modified from Akira S 2006 Cell (46)

TABLE 1. Toll-like receptors and their ligands
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Certain TLRs (TLRs 1, 2, 4, 5, and 6) are expressed on the cell surface while others (TLRs
3, 7, 8, and 9) are found almost exclusively in intracellular compartments such as
endosomes (46-48) (Figure 2). Intracellular TLRs recognize nucleic acids, suggesting that
degradation of the viral particles or the bacterial cell walls might be needed to release the
microbial nucleic acids and allow their recognition by TLRs.

FIGURE 2. TLR localization

8

TLR common signaling pathway (MyD88-dependent pathway)
Ligand binding by TLRs results in receptor dimerization and conformational
changes required for the recruitment of TIR-domain-containing adaptor molecules to the
TIR domain of the TLR. Four adaptor proteins, MyD88 (myeloid differentiation factor
88) (49-50), MAL/TIRAP (MyD88-adaptor-like/TIR-associated protein) (51-54), TRIF
(Toll-receptor-associated activator of interferon) (55-56) and TRAM (Toll-receptorassociated molecule) (56-57) have been identified. MyD88 is essential for responses
against a broad range of microbial components since MyD88-deficient mice display
impaired cytokine production when exposed to IL-1 (58) or the TLR2-4-5-7or 9 ligands
(59-62). MyD88 is characterized by the presence of a TIR domain that interacts with the
cytoplasmic domain of the TLRs and IL-1R, and a death domain (DD) that binds DD
containing proteins situated downstream in the signaling pathway. Serine-threonine
kinases that belong to the interleukin-1 receptor-associated kinase (IRAK) family contain
an N-terminal DD. MyD88 functions as an adaptor recruiting IRAK4 and IRAK1
proteins to the TLRs/IL-1Rs through interaction with their DD domain. Activated IRAK1
auto-phosphorylates residues in its N terminus and recruits TNF receptor associated
factor 6 (TRAF6) to the TIR signaling complex. The IRAK1–TRAF6 complex then
uncouples from the receptor and interacts at the plasma membrane with members of the
mitogen-activated protein kinase kinase kinase (MAPKKK) family transforming growth
factor β–activated kinase (TAK) and TAK-1-binding protein (TAB). This interaction
induces phosphorylation of TAB2/TAB3 and TAK1, which then translocate together with
TRAF6 and TAB1 to the cytoplasm. TAK1 is subsequently activated in the cytoplasm,
leading to the activation of inhibitor of kappaB factor kinases (IKKs) and MAPKs.
9

MAPKs activate the transcription factor activating protein-1 (AP-1) while activated IKKs
phosphorylate the inhibitors of kappaB (IκBs) leading to their degradation and
consequently the release of nuclear factor kappa B (NFκB) (Figure 3).

FIGURE 3. TLR common signaling pathway
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The activated NFκB complex translocates into the nucleus and binds the DNA at
kappa-B-binding motifs. As a result NFκB and AP-1 (46) activate genes that code for
cytokines, chemokines, growth factors and cell adhesion molecules.
TRIF dependent pathway (MyD88-independent pathway)
LPS stimulation results in MAPK activation and recruitment of NFκB to the
nucleus in MyD88-deficient macrophages even when cytokine production was impaired
(59). Furthermore, LPS-treatment induces MyD88-deficient DC maturation as
demonstrated by upregulation of costimulatory molecules (CD80, CD86 and CD40) and
increased ability to induce T cell proliferation (55-56). These data demonstrates the
existence of a MyD88-independent pathway/s that can be activated by specific TLR
ligands but not all since TLR2-5-7 and 9 signaling is completely abrogated in MyD88deficient cells (60-62). Analysis of the gene expression pattern elicited by LPS in
MyD88- deficient macrophages identified IFN-β and IFN-inducible genes (63).
TRIF (also known as TICAM1) was identified as an interacting partner with
TLR3 by yeast two-hybrid screening (64). Following generation of TRIF-deficient mice,
it was revealed that they were impaired in the induction of IFN-β and IFN-inducible
genes by the TLR3 and TLR4 ligands. Furthermore, activation of IRF3, a transcription
factor involved in the induction and response to type I IFNs, was also impaired (56). The
downstream events of TRIF activation that result in NFκB and IRF3 activation are still
unclear. NFκB activation by TRIF might depend on TRAF6 meanwhile TANK binding
kinase (TBK)-1 has been shown to be involved in IRF3 activation (65).
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TLR7 and TLR9 also induce type I IFN production in addition to
proinflammatory signals. Interestingly, TLR7- and TLR9-mediated IFN-α secretion
occurs in a MyD88-dependent manner (66-68), in contrast to TLR3- or TLR4-mediated
IFN responses, which are dependent on TRIF but not on MyD88.
Other TIR-domain containing proteins
TRAM
TRAM associates with TLR4 and TRIF suggesting that its function is to bring
them together (57). LPS induced production of IFN-β and IRF3 activation are impaired in
TRAM-deficient mice indicating that TRAM is involved in the activation of the MyD88independent pathway by TLR4 (69).
TRAM’s role as an adaptor might be specific for TLR4 signaling since cytokine
production by TLR2 -3-7 and 9 ligands remained intact in TRAM-deficient mice (69).
MAL/TIRAP
Expression of dominant-negative TIRAP, which encodes only the TIR domain,
blocked NFκB activation by TLR4 (51). Furthermore TIRAP-deficient mice are impaired
in inflammatory cytokine production and activation of the NFκB and MAPK pathways
induced by TLR1-2-4 and -6 ligands. In contrast, the TLR4-mediated maturation of DCs
and activation of IRF3 were intact in TIRAP-deficient mice (52). As explained above
IRF3 activation and DC maturation can be achieved by the TRIF-dependent pathway
alone, suggesting that TIRAP participates in the MyD88-dependent pathway of specific
TLRs.

12

TLR5 and flagellin
Flagella are complex organelles that play a major role in bacterial motility and
chemotaxis. The body of the flagellum consists of a mass of protofilaments, each of
which is a long, end-to-end polymer of a single protein, flagellin. Many important human
pathogens are flagellated and for a long time expression of flagella has been examined as
a virulence trait, but this examination has been largely in the context of motility rather
than immune stimulation (70-72). As mentioned before TLRs are characterized by the
presence of an intracellular TIR domain shared by them and the IL-1R. TLR5 was
identified in human and mice based on the presence of the TIR domain (73). TLR5 is
expressed in epithelial cells, endothelial cells, macrophages, DCs, and T cells (72). Initial
identification of flagellin as the ligand for TLR5 came from a study that isolated
stimulatory components from Listeria culture supernatant proteins by high-performance
liquid chromatography (HPLC) (61). Parallel studies examining the activation of
epithelial cells in response to Salmonella also identified flagellin as a stimulatory ligand
for TLR5 (74). Analysis of the flagellin amino acid sequences from Gram-positive and negative bacteria revealed the presence of highly conserved sequences at the amino and
carboxyl termini (75). TLRs target conserved sequences making the carboxy- and aminoterminus the predictable candidates for TLR5 recognition. Studies from Eaves-Pyles et al
initially confirmed this hypothesis. In their study constructs consisting of only the amino,
central or carboxy regions of flagellin lacked stimulatory capacity, as evaluated by in
vitro activation of NFκB and IL-8 production in intestinal epithelial cells. However, a
fusion protein composed of the conserved amino and carboxyl termini, induced a
response that was identical to the response induced by wild-type flagellin suggesting that
13

both ends of the protein but not the central variable region are needed for flagellin
recognition by TLR5 (76). Further and deeper studies by Aderem’s group targeted the
specific location of the TLR5-flagellin interaction to a group of amino acids from both
ends brought together in the folded protein (77). Interestingly, mutation of those specific
residues greatly diminished the bacteria’s motility (77) supporting the paradigm that
TLRs target molecules that are conserved since their mutation would affect functions that
are vital for the microorganism.
TLR5’s binding site is buried within the flagella since it acts as part of the
anchorage region that binds one monomer to another in order to form the flagellum
filament (Figure 4). Accordingly, it has been shown by cross-linking studies that flagellin
monomers are much more potent than polymers to elicit TLR5 activity (77). It is not yet
clear how the internal structure of the flagellum filament would come in contact with
TLR5. One possibility is that flagellin monomers are released in the phagosome or may
be exposed during the flagellum assembly. A surprising finding is that lysophospholipids
produced by epithelial cells stimulate the synthesis and release of monomeric flagellin
from Salmonella (78). It is unclear how this evidence affects our understanding of
Salmonella infection but it could be that through induction of inflammatory mediators
and consequently the recruitment of inflammatory cells to the site of infection,
recognition of flagellin promote systemic dissemination of the pathogen. Supporting this
conclusion TLR5-/- mice survived oral Salmonella infection better than wild-type mice
as shown in a recent work from Uematsu et al (79).
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B
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(76)

FIGURE 4. TLR5 binds the conserved domains in flagellin
The flagella present in the different species of Salmonella (A) are polymers of the protein
flagellin. The flagellin monomers are assembled leaving the D3 and D2 domains exposed
while the D1 domain is enclosed within the filament structure (B). The exposed region of
the flagella will act as a paddle to facilitate the bacterial movement while the internal part
is necessary for its assembly. TLR5 binds a group of aminoacids from the carboxy and
amino terminus that are brought together in the folded protein as part of the D1 domain
(C). Probably due to their structural role aminoacids in the D1 domain are highly
conserved among flagellated bacteria while the other domains show a much higher
variability.
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TLR5 in the epithelia
The epithelial surfaces of the host represent principal entry sites for many
pathogens and the expression of TLR5 by epithelium allows for rapid recognition of
flagellated organisms. Studies by Gewirtz et al. identified flagellin as the bacterial factor
inducing IL-8 production following the interaction of Salmonella with human intestinal
epithelial cells (74). The effects of flagellin on epithelial gene expression are not
restricted to interleukin-8, but rather flagellin has been shown to be Salmonella’s
dominant proinflammatory determinant, being necessary and sufficient for nearly all
induction of epithelial proinflammatory gene expression induced by Salmonella
typhimurium (80). Interestingly, the activation of this inflammatory response was
dependent upon the translocation of flagellin to the basolateral surface of the epithelial
cells, where TLR5 is expressed (81). Presumably, this requirement limits epithelial cell
activation to pathogens that can translocate flagellin, and therefore, avoids TLR5 ligation
by the normal intestinal flora since flagellin expression is not restricted to pathogens but
rather is expressed by all motile bacteria. TLR5 is also highly expressed in the airway
epithelia and it is a potent inducer of inflammation in the lung (82). Flagellin detection
plays an important role in the defense against pathogens of the respiratory tract since
suppressing TLR5 signaling increases susceptibility to infection by Legionella (83).
TLR5 and innate immunity
Flagellin has been shown to induce production of cytokines and upregulation of
costimulatory molecules from human DCs (84). The results with mouse DCs have been
more controversial and while TLR5 expression and flagellin-induced maturation of
mouse splenic and BM derived DCs have been reported by several groups (85-87), others
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found murine DCs not to be responsive to flagellin stimulation due to very low or absent
TLR5 expression (79) (84). The cause for these discrepancies is not clear since the purity
of the flagellin preparation is well documented in the majority of these studies. One
possibility is that these discrepancies are due to the plasticity of TLR expression on APCs
that is rapidly modulated in response to cytokines and environmental stresses. Uematsu et
al. recently demonstrated that high levels of TLR5 are expressed by murine lamina
propria DCs. These DCs when stimulated with flagellin produced high levels of IL-6, IL12 but not IL-10 (79). Interestingly, DCs from the gut stimulated with microbial products
or CD40L have been shown to produce higher levels of IL-10 than those from the spleen
(88). IL-10 production by intestinal DCs probably plays an important role in the
establishment of tolerance towards commensal bacteria and food antigens through the
development of regulatory T cells. In contrast, the cytokine profile seen in flagellin
stimulated lamina propria DCs (production of proinflammatory cytokines in the absence
of IL-10) suggests that these cells would induce inflammatory responses rather than
tolerance. These data supports the prior notion that flagellin plays an important role in
eliciting inflammatory responses in the gut.
TLR5 and adaptive immunity
Flagellin’s ability to work as an adjuvant for T cell responses has been evaluated
by several studies. The first report came from Gewirtz group demonstrating that
Salmonella’s flagellin was capable of enhancing antigen specific CD4+ T cell expansion
and memory development in vivo. Antigen-specific transgenic T cells primed in vivo with
antigen in the presence of flagellin produced IFN-γ but not IL-4 upon in vitro
restimulation suggesting that flagellin induces Th1-biased responses in vivo (89). These
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data is at odds with reports from other groups supporting that flagellin induces a Th2
response in vivo. In the latter a Th2 antibody response was observed in flagellin
immunized animals followed by the production of IL-4 and IL-13 by lymph node cells
restimulated in vitro (85).
In addition to flagellin’s ability to prime the adaptive immune response through
its effects on APCs, recent evidence supports that flagellin could also directly stimulate
lymphocytes. Expression of mRNA from different TLRs has been detected in human and
murine T cells among them TLR5. In addition, flagellin has been shown to increase
proliferation and IFN-γ production by memory-effector T cells and also to directly
enhance IL-2 production and proliferation by naïve T cells (90-91). In murine and human
T cells, TLR5 expression has been shown to be selectively enhanced in CD4+CD25+ T
cells as compared with their CD4+CD25- naïve counterparts (91-92). Furthermore,
treatment of human CD4+CD25+ T cells with flagellin increased their ability to suppress
the proliferation of naïve T cells stimulated with anti-TCR and anti-CD28 antibodies
(91). Forkhead box p3 (FOXP3) is a transcription factor directly related with regulatory T
cell development as FOXP3-transfected naïve T cells suppressed inflammatory responses
in vitro and in vivo (93). Interestingly, treatment of CD4+CD25+ T cells with flagellin
increased FOXP3 expression which could explain the enhancement of the suppressive
phenotype observed in flagellin-treated regulatory T cells (91).
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IL-10 and IL-12
Recognition of viral or bacterial products through TLRs induces profound
changes in APCs, many of them directed towards cytokine production (45). Cytokines act
as cellular messengers shaping and expanding the immune response, furthermore they are
responsible to terminate an ongoing response before tissue damage might occur. The
cytokines IL-12 and IL-10 play key roles in expanding and limiting inflammation usually
acting in opposition.
IL-12
Macrophages, monocytes, neutrophils, and DCs, are the main sources of IL-12
(94). The biologically active form of IL-12, IL-12p70, is a heterodimer formed by a 35kDa light chain (known as p35 or IL-12α) and a 40-kDa heavy chain (known as p40 or
IL-12β) (95). IL-12p40 has been shown to be produced in excess over IL-12p35
suggesting that IL-12p35 acts as a limiting factor for IL-12p70 formation (96). IL-12p40
can be secreted as a monomer but not IL-12 p35 that is secreted only when associated
with p40 (96). IL-12p40 homodimers have been observed in mice in vivo but their
function has not been completely elucidated (97-99).
Regulation of IL-12 production
IL-12 p35 and IL-12p40 are encoded by two genes located in different
chromosomes and regulated independently. Regulation of IL-12p40 expression has been
reported to occur only at the transcriptional level while IL-12p35 might be regulated by
transcriptional and translational mechanisms (100). The endogenous p40 promoter is
assembled in four tightly positioned nucleosomes (101) and therefore is not accessible to
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the transcriptional machinery. LPS stimulation has been shown to result in chromatin
remodeling that allows binding of the transcription factor CCAAT enhancer-binding
protein (C/EBP) (102). However, C/EBP by itself is not enough to induce IL-12p40
transcription and cooperation with other elements as NFκB is necessary (94).
The low levels of IL-12p35 expression even in activated cells have complicated
the study of the mechanisms that regulate its transcription. Nonetheless, cloning of the
IL-12p35 promoter region from murine and human cells have served to identify binding
sites for the transcription factors specificity protein 1 (SP1), IFN-γ response element (γIRE) and C/EBP (103-104).
TLR activation by microbial products is the strongest stimulus to induce IL-12
production that can be further enhanced by the cytokines IFN-γ and IL-4 (105-106). On
the contrary, IL-10 plays a major role in the negative regulation of IL-12 production by
blocking transcription of the p40 and p35 genes (107-108).
IL-12 biological activity
The IL-12 receptor (IL-12R) is mainly expressed in activated T and NK cells
making them the main target for this cytokine (94). Engagement of the IL-12R, as other
cytokine receptors, activates the Janus kinase (JAK) family of protein tyrosine kinases,
which in turn activate cytoplasmic signal transducer and activator of transcription
(STAT) proteins. Activated STATs dimerize and translocate to the nucleus, where they
induce expression of STAT-regulated genes (109). Although STAT1-3-4 and 5 have been
reported to be activated by the IL12 receptor (110), STAT4 appears to be the major
player in the IL-12-induced response (111-112). The proinflammatory nature of IL-12 is
mainly due to its strong ability to induce IFN-γ production by T cells and NK cells. IL-12
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is required for differentiation of CD4+ T cells into IFN-γ producing T helper cells that are
denominated T helper 1 (Th1) cells. Th1 cells are fundamental in the development of
cellular immune responses as the differentiation of cytotoxic CD8+ T cells (CTLs) and
increase phagocytosis and microbial killing by members of the innate immune system
(94). Treatment with IL-12 has been shown to have a marked anti-tumor effect on mouse
models by inhibiting the establishment or inducing the regression of tumors (113). The
anti-tumor effect of IL-12 is complex and involves not only antigen-specific responses
against the tumor but also the production of inflammatory mediators that block
angiogenesis and/or have a direct toxic effect over the tumor (113). Finally, the powerful
proinflammatory nature of IL-12 plays a central role not only in the immune responses
against tumors and pathogens but also in the development of organ-specific
autoimmunity (114).
IL-10
IL-10 was discovered in the early 1990s by Mossman’s group using an assay to
isolate factors that could suppress T cell activity (115). Later on, the same group and
others showed that IL-10 acted indirectly, via APCs, to block T cell function (116-117).
The current understanding is that IL-10 primarily acts by inhibiting a broad spectrum of
activated functions in macrophages and dendritic cells. The functions inhibited include
cytokine and chemokine production and expression of MHC class II and costimulatory
molecules such as CD80 and CD86 (118-121).
Regulation of IL-10 production
The molecular mechanisms that regulate expression of the IL-10 gene are poorly
understood. The transcription factors specificity protein (Sp) 1 (122-123), Sp3 (123),
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CCAAT/enhancer-binding protein(C/EBP)-β (124), IFN regulatory factor 1 (IRF-1), and
STAT3 (122) have been reported to be involved in IL-10 transcription and among them
Sp1 seems to play a central role in the induction of IL-10 by LPS in macrophages (122).
Sp1 is ubiquitously expressed suggesting that other mechanisms of control exist to ensure
IL-10 production upon stimulation and not in a constitutive manner. One mechanism
would be through restricted accessibility to the promoter. Supporting this possibility ERK
activation by LPS and other stimuli results in histone 3 (H3) phosphorylation at specific
regions of the IL-10 promoter and enhanced chromatin accessibility (126). Furthermore
mRNA stability might also play an important role in IL-10 regulation as the presence of
AU-rich elements that increase mRNA degradation have been described in the IL-10
mRNA (127).
IL-10 biological activity
Macrophages, DCs and certain T cell subsets are the main source of IL-10. The
main targets seem to be the antigen presenting cells even when the IL-10 receptor (IL10R) is expressed in most hematopoietic cells (128-129). IL-10R signaling results in the
activation of STAT3 (121). STAT3 activation is essential for the anti-inflammatory
properties of IL-10 signaling since blockade of the STAT3 function abrogates IL-10
mediated suppression of LPS-induced cytokines and costimulatory molecules (130-132).
Conversely, constitutively activated STAT3 recreates the anti-inflammatory effects
induced by IL-10 (133). The anti-inflammatory response induced by IL-10 has been
shown to require the synthesis of new proteins suggesting that STAT3 induces one or
more genes that execute the anti-inflammatory response but the identity of these proteins
is still unknown (134).
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IL-10 deficient mice spontaneously develop chronic intestinal inflammation as a
result of aberrant immune responses to the microbiota of the gastrointestinal tract (135).
Disease development depends on IL-12 and requires the presence of resident enteric
bacteria (136). Furthermore upon bacterial and fungal infection these mice develop strong
Th1 responses that results in enhanced clearance of the pathogen but also in toxicity and
death due to massive inflammatory responses (137-138). Disease development in IL-10
deficient mice demonstrates that IL-10 is essential to limit immune responses and other
factors can not compensate for its loss.
Elevated IL-10 serum levels have been reported as a negative prognostic factor
for survival in lymphoma, lung cancer, hepatocellular, renal or gastric carcinoma and
other solid tumors (121). How IL-10 contributes to a poor prognosis for some cancers is
not completely elucidated and probably its role might vary for different malignancies.
Nonetheless, it is clear that the presence of IL-10 will blunt the induction of an immune
response against tumor cells by inhibiting DC function. Furthermore, IL-10 might serve
as a growth factor for certain cell types as B cells (139).
The main objective of tumor immunotherapy is to induce productive and specific
immune responses against malignant cells. The powerful proinflammatory nature of TLR
ligands led us to explore the possibility of using them to achieve this goal. Among all
TLR ligands, flagellin is the only protein, this characteristic facilitates its use for
vaccination purposes as it can be cloned or modified easily. Therefore, we decided to
focus our research in flagellin and its receptor (TLR5). The goals of our project were
basically two. First, characterize the response elicited by TLR5 in APCs. Second,
evaluate the ability of flagellin to prime immune responses in tolerogenic conditions.
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Furthermore, we also investigated the translation of these studies into a suitable antitumor vaccination strategy.

24

MATERIALS AND METHODS
TLR ligands.
Salmonella typhimurium flagellin was isolated as previously described (140).
Briefly, Salmonella typhimurium is grown in a chemically defined media, in order to
avoid the contamination of the flagellin preparation with other proteins. The dissociation
of flagella from the bacterial cells was achieved by reducing the pH to 2.0 with HCl for
only 30 min. The reduction in pH results in the detachment and breakdown of flagella
into its monomeric form, but it does not cause the death or disruption of the bacteria. The
monomeric form of the flagella, flagellin protein, is no longer centrifugable. This
property is exploited to remove pH 2.0 insoluble contaminants before protein
precipitation. Protein precipitation was achieved by saturating the preparation with
ammonium sulfate (2.67 M final concentration). After which the protein precipitate is resuspended in an appropriate volume of endotoxin free water and dialyzed overnight in
distilled water plus activated charcoal. Even after all these purification steps the presence
of small amounts of endotoxin in the protein preparation were detectable using the
Limulus Amebocyte Lysate method (Cambrex, Rutherford, NJ). Further purification
steps combining filtration through 100 Kd pore size centricon columns (Millipore,
Billerica, MA) and polymixin B columns, Detoxi-Gel AffinityPak columns (Pierce,
Rockford, IL) were used to remove the remaining LPS.
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SDS-PAGE analysis revealed no contaminating proteins accompanying the
expected flagellin doublet at around 50kDa. In addition western blot using a monoclonal
antibody

against

flagellin

further

confirmed

the

protein’s

identity

(Igen

international,Gaithersburg, MA). In those experiments in which flagellin was digested
with proteinase K (Sigma Aldrich, St Louis ,MO ) 100 μg/ml proteinase K were used,
digestion carried for 4 hours at 37°C and the protease was inactivated at 100°C for 1
hour. Experiments were also performed with commercially available S. typhimurium
flagellin (InVivoGen, San Diego, CA) which yielded identical results. LPS was obtained
from Sigma (Sigma, St Louis, MO). CpG, and Zymosan were obtained from InVivoGen,
(InVivoGen,San Diego, CA) and they were used as indicated in the text.
Isolation of peritoneal elicited macrophages (PEM) and generation of bone marrow
(BM)-derived macrophages.
BALB/c mice were injected intraperitoneally with 1 mL of thioglycollate (DIFCO
Laboratories, Detroit, MI). Four days later, PEMs were obtained by peritoneal lavage as
previously described (141). For CK analysis by ELISA 105 cells per well are plated in a
96 well plate, for RNA analysis 1 x 106 cells per well are plated in a 24 well plate. After 2
hours those cells that did not adhere to the plate are washed off using ice-cold HBSS (2
washes).
BM-derived macrophages were differentiated from bone marrow cells by
harvesting the hind legs and flushing the bone marrow with RPMI. Red blood cells were
lysed using ACK lysis buffer and the remaining cells extensively washed. Differentiation
of bone marrow cells into macrophages was achieved by 5-6 days incubation of the cells
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in complete media (20% FBS, 100μM β-mercapto-ethanol in DMEM) supplemented with
L-929 cells supernatants as a source of M-CSF (142). At the end of the incubation period
the plates are washed vigorously with ice-cold HBSS and the strongly attached cells are
macrophages. FACS analysis of these cells showed that they are CD11b high Gr1 low/+
Quantification of cytokines
Mice were treated with flagellin (10 μg/animal), LPS (10 μg/animal) or HBSS
and the volume injected was 0.1 ml via tail vein. Ninety minutes later the animals were
sacrificed and blood obtained by heart puncture. Blood was spun down at maximum
speed in a minicentrifuge to separate the serum from the cellular components of the
blood. Cytokine levels were quantified by sandwich ELISA following manufacturer’s
instructions (BD Pharmingen, San Diego, CA). For in vitro determination of cytokine
production, 1x105 PEMs were plated by triplicate in 96 well-plates and treated for 24
hours unless otherwise specified. Supernatants were harvested and kept at -70°C until
ELISA for IL-10; IL12p40-70 (BD Pharmingen, San Diego, CA) or IL-12 p70
(Ebioscience San Diego, CA) was performed following manufacturer’s instructions
Real time (RT)-PCR analysis.
Two million PEMs or BM-derived macrophages were plated per well in a 24 well
plate. After 2 hours non-adherent cells were washed off with media and attached cells
were then treated as indicated. Total RNA was extracted using TriZol reagent
(Qiagen,Valencia,CA) and cDNA obtained with the iScript cDNA synthesis kit (BioRad,Hercules,CA). Target mRNA was quantified using MyIQ single color real time PCR
detection system (Bio-Rad) and iQ SYBR green Supermix (Bio-Rad,Hercules,CA). IL27

12p35

primers

(left

oligo

ATGGTGAAGACGGCCAGAG,

CAGGTCTTCAATGTGCTGGTT)

IL-12p40

primers,

right
(left

oligo
oligo

GCAACGTTGGAAAGGAAAGA, right oligo AAAGCCAACCAAGCAGAAGA), IL10

primers

(left

oligo

CAGGGATCTTAGCTAACGGAAA,

GCTCAGTGAATAAATAGAATGGGAAC),

TLR5

primers

right
(left

oligo
oligo

GCATAGCCTGAGCCTGTTTC, right oligo AAGTTCCGGGGAATCTGTTT) and
GAPDH

primers

(left

oligo

ATGGCCTTCCGTGTTCCTAC,

right

oligo

CAGATGCCTGCTTCACCAC) were used for PCR amplification (cycling parameters 3
min 95°C, 15 secs 95 °C, 30 secs 60°C 40 reps, 1 min 95°C). Single product
amplification was confirmed by melting curve analysis and primer efficiency was near to
100% in all the experiments performed. Quantification is expressed in arbitrary units and
target mRNA levels were normalized to GAPDH expression.
Preparation of flagellin-coated beads
Carboxyl (COOH) microparticles (Fluoresbrite YG carboxylate microspheres 1
μm Polysciences Inc, Warrington, PA) were used for covalent coupling of flagellin by
activating the carboxyl groups with water-soluble carbodiimide. The carbodiimide reacts
with the carboxyl group to create an active ester that is reactive toward primary amines
on the protein of interest (PolyLink Protein Coupling Kit for COOH Microspheres
Polysciences Inc, Warrington, PA)
Antigen-specific T-cell tolerance model.
Single cell suspensions were made from peripheral lymph nodes and spleen
collected from anti-HA TCR transgenic donors (BALB/c HA+/- mice). The percentage of
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lymphocytes double positive for CD4 and the clonotypic TCR was determined by flow
cytometry. Cells were washed three times in sterile Hanks balanced salt solution (HBSS),
and injected into the tail vein of male recipients such that a total of 2.5x106 CD4+ antiHA TCR+ T cells were transferred into BALB/c mice. One day later, mice were injected
intravenously (i.v) with a tolerogenic dose of HA-peptide110-120 (200 μg) in combination or not- with 10 μg of flagellin. Two weeks later the animals were sacrificed and the
spleen harvested. Transgenic T cells numbers in the spleen were assessed by Flow
Cytometry with FITC conjugated rat anti mouse CD4 antibodies (Pharmingen) and
byotinilated rat anti-clonotypic TCR antibody MAb 6.5 (kindly provided by Dr Hyam
Levitsky, John Hopkins University) and analyzed by Flow-Jo software (Treestar Inc). For
in vitro restimulation analysis, splenocytes were plated by triplicate in a 96 well plate at a
final concentration of 1x106 cells per well, in the presence or not of synthetic HApeptide110-120. After 48 hours stimulation supernatants were collected and the production
of IFN-γ and IL-2 was assessed by ELISA. Values for cells cultured in media alone are
less than 10% of the values for antigen-stimulated cells. Data are expressed as the amount
of cytokine produced by 100 clonotype+ T cells/well.
Cell lysates and western blot
Total cell lysates were prepared in RIPA buffer (150 mM NaCl, 10 mM Tris-HCl,
pH 7.4, 5 mM EDTA, pH8.0, 0.1% SDS, 1% deoxycholate, 1% Triton X-100) containing
protease inhibitors cocktail (Sigma Aldrich, St Louis ,MO ) and phosphatase inhibitors
cocktail (I and II) (Sigma Aldrich, St Louis ,MO )

and subjected to SDS-PAGE-

immunoblot analysis with anti-phospho-p44/42 MAPKinase (Thr202/Tyr204) polyclonal
antibody (Cell Signaling), phospho-IkappaB-alpha (Ser32) (14D4) rabbit monoclonal
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antibody (Cell Signaling) and anti-MAPKinase (ERK1+ERK2) monoclonal antibody
(Invitrogen)
Generation of DCs.
Dendritic cells were differentiated as in (146). Briefly bone marrow was collected
from the femur and tibia of 6-10 week old BALB/c mice. Red blood cells were lysed in
ACK lysis buffer and CD4+, CD8+ cells depleted using complement-mediated lysis
followed by extensive washing. Cells were cultured for 7 days in media supplemented
with 20 ng/ml GM-CSF plus 20 ng/ml IL-4 (BM-DCs) or 20 ng/ml GM-CSF plus 40
ng/ml IL-10 plus 2.5 ng/ml TNF-α (as already documented (144) we noticed that the
addition of TNF-α did not alter the DCs phenotype or ability to produce cytokines but it
helped to expand the yield of these cells.). Every 2 days old media was removed from the
plate and fresh media added. After 7 days in culture cells were harvested. Around 90% of
the cells harvested were CD11c + as determined by FACS analysis.
Naïve T cell preparation and in vitro differentiation
Naïve T cells were purified from HA +/- BALB/c mice using magnetic column
separation. The phenotype of these T cells (CD4+ CD62L+) was confirmed by FACS
analysis before culture and cells plated with BM-DCs or tolerogenic-DCs and antigen for
7 days. After this incubation period cells were washed twice with ice cold HBSS and
transferred to a new plate where they were restimulated using fresh splenocytes as APCs
plus antigen (HA peptide). After 48 hours restimulation supernatants were collected and
CK production was quantified by ELISA. T cell proliferation was assessed after 72 hours
restimulation by pulsing the cells with [3H]thymidine (1 μCi/well, NEN Life Science,
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MA). Eighteen hours later, cells were harvested with a Packard Micromate cell harvester
and thymidine incorporation into DNA was measured as counts per minute (cpm).
FliC expressing tumor cells
The

ATTCAGTGCCGATACCAAGG

(left

primer)

and

ACGTGTCGGTGAATCAATC (right primer) oligos were designed to amplify the whole
fliC coding sequence from Salmonella typhimurium (Genbank accession number
D13689). The PCR product was identified as a unique band running at the expected size
of 1.6 Kb and purified from the agarose gel using the Qiaquick gel extraction kit
(Qiagen).

The PCR product obtained was initially cloned into the pCR 2.1 vector

(Invitrogen TA cloning kit).

The proper orientation of the insert was verified by

sequencing using an oligo for the T7 promoter present in the plasmid. Following this
step, the construct was digested with the restriction enzymes XhoI and HindIII and
subcloned into the pcDNA 3.1 (-)Hygro vector (Invitrogen) for IL-10 protein expression
in mammalian cells. The inserted fragment was sequenced and identified as the fliC gene
of Salmonella typhimurium.
The pcDNA 3.1/fliC construct was then used to transfect the murine melanoma
cell line B78H1 using the Lipofectamine plus reagent (Gibco). Transfected cells were
initially selected in complete media plus 400 μg/ml of Hygromicin. Cells that survived
were further selected in media containing 1200 μg/ml of Hygromicin.

Flagellin

expression by these cells was confirmed by western blot analysis of cell lysates using an
anti-flagellin specific monoclonal antibody (Igen International).
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RESULTS
Flagellin preparation
Flagellin was purified from Salmonella typhimurium as explained in the Materials
and Methods section. Briefly, the dissociation of flagella from the bacterial cells was
achieved by reducing the pH to 2.0 with HCl for 30 min. The reduction in pH results in the
detachment and breakdown of flagella into its monomeric form, but it does not cause the
death or disruption of the bacteria. Soluble flagellin is precipitated using ammonium
sulfate at saturating conditions and further purified using dialysis, ultrafiltration and
polymyxin B beads to eliminate endotoxin contamination.
SDS-PAGE analysis of the flagellin preparation revealed no contaminating
proteins accompanying the expected flagellin doublet at around 50kDa (Figure 5A).

FIGURE 5. Flagellin protein
preparation
(A) SDS PAGE followed by
Coomasie staining of a Salmonella
flagellin preparation. (B)Western
blot analysis of the same protein
preparation using monoclonal
antibodies against flagellin

77 kd
50 kd
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The presence of two bands is due to the expression of two different flagellin
proteins by wild type Salmonella known as FliC (flagellin phase type 1/H1) and FljB
(flagellin phase type 2/H2) (145). The FliC and FljB Salmonella flagellin proteins display
78% sequence identity and seem to activate TLR5 signaling with similar potency (145).
The identity of both proteins was verified by western blot using a monoclonal antibody
against flagellin (Figure 5B).
Flagellin-stimulated PEM produce IL-12 but not IL-10
Peritoneal elicited macrophages (PEM) were treated in vitro with increasing
concentrations of purified flagellin or with LPS for 24 hours. At this time the
supernatants were collected and production of IL-12 p40/p70 and IL-10 was determined
by ELISA. Reminiscent of previous studies (121), LPS-treated PEM produce both the
proinflammatory cytokine IL-12 as well as the anti-inflammatory cytokine IL-10 in a
dose-dependent manner (Figure 6A). Treatment of PEM with flagellin also resulted in a
dose dependent production of IL12p40/p70 (Figure 6B). The magnitude of this response
was however not as potent as the one induced by LPS (Figure 6A versus 6B, black
squares). IL-10 is commonly produced by macrophages upon stimulation with different
TLR ligands, but to our surprise we did not detect any IL-10 production in flagellinstimulated PEM (Figure 6B-open squares). The lack of IL-10 production was not the
result of delayed production of this cytokine since kinetic studies showed that even after
72 hours of treatment IL-10 was still not detected in the supernatants of flagellin-treated
PEM (Figure 6C-open squares). In contrast, when PEM were stimulated with LPS, IL-10
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was detected at early time points and its levels remained elevated throughout the duration
of the incubation period (Figure 6C-open diamonds).
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FIGURE 6. IL-12p40-70 but not
IL-10 is detected in the
supernatants
of
flagellinstimulated PEM.
(A-B) PEM from BALB/c mice
5
(1x10 cells/well) were cultured for
24 hours with the indicated
concentrations of LPS, flagellin or
proteinase K digested flagellin
(FD, volume added equivalent to 5
µg/ml flagellin) Supernatants
were
then
collected
and
IL12p40/70 or IL-10 were
determined by ELISA. Data
represent mean ± s.d. of triplicate
cultures. Shown is a representative
experiment of three independent
experiments with similar results.
(C) PEM were treated with
flagellin (5 µg/ml), LPS (1 µg/ml)
or with HBSS. Supernatants were
collected at the indicated time
points and the production of IL-10
was determined by ELISA. Data
represent mean ± s.d. of triplicate
cultures. Shown is a representative
experiment of two independent
experiments with similar results.
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One concern in the interpretation of the results described above is the possibility
that the flagellin preparation would be contaminated with other bacterial products that
could activate macrophages, especially lypopolysaccharide (LPS). However we have
used several controls to rule out this possibility. First, we tested the flagellin preparation
with the Limulus amebocyte lysate test (LAL). This chromogenic method is based on the
activation of a proenzyme on the lysate when in contact with endotoxin and it is of
standard use in pharmaceutical and medical facilities. Using this test we could not detect
LPS contamination in our flagellin preparation. Second, digestion of the flagellin
preparation with proteinase K resulted in loss of its ability to induce IL-12 production in
PEM (Figure 6B-FD, and Figure 7A) indicating that this effect is induced by a protein
and not by other non-proteinaceous potential contaminants in the preparation. Finally,
given the previous demonstration that the inflammatory effect of flagellin requires
binding to TLR5 (61) (79), we treated the macrophage cell line RAW 264.7, which lacks
TLR5 (146 and Figure 7B), with flagellin or LPS. While treatment with LPS resulted in
IL-12 production by these cells, treatment with flagellin failed to induce such a response,
indicating that induction of IL-12 by flagellin requires expression of TLR5 in the target
cell (Figure 7C). The absence of IL-12 production in RAW 264.7 cells also provides
additional support to our claim that the flagellin preparation used in our experiments was
LPS-free, since some LPS contamination might have otherwise resulted in IL-12
production by RAW 264.7 cells. To conclude, our data shows that the observed effects
induced by flagellin on macrophages are not due to LPS contamination and require
expression of TLR5 in the responding cells.
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FIGURE 7. IL-12 p40-70
production
by
flagellinstimulated macrophages is not
caused
by
endotoxin
contamination
(A) Proteinase K digested flagellin
does not induce IL-12 production
by PEM. Peritoneal macrophages
were cultured in media alone or in
the presence of flagellin (5 μg/ml)
digested or not with proteinase K.
Supernatants were collected after
24 hours and IL-12 p40-70 was
quantified by ELISA. Shown is one
of at least three experiments made.
(B) and (C) RAW 264.7 do not
express detectable TLR5 mRNA
levels and do not respond to
flagellin stimulation. (B) TLR5
mRNA level from PEM or RAW
264.7 cells was determined by
quantitative real-time RT-PCR.
GAPDH mRNA levels were similar
among the samples compared.
Shown
is
a
representative
experiment of two independent
experiments with similar results.
(C) RAW 264.7 cells were cultured
for 24 hours with flagellin
(5µg/ml), LPS (1 µg/ml) or media
alone. Supernatants were collected
and the levels of IL12p40/70 were
measured by ELISA. Data
represent mean ± s.d. of triplicate
cultures from a representative
experiment of three with similar
results.

IL-12 but not IL-10 is detected in the serum of flagellin-treated mice.
To confirm the above in vitro results, we assessed next the production of IL-10 and
IL-12 in mice that received a single intravenous (iv) injection of either flagellin or LPS. As
shown in Figure 8A, similar levels of IL-12 p40-70 were detected in the serum of LPS or
flagellin treated mice. In contrast, IL-10 production showed a completely divergent
outcome upon treatment with either TLR ligand. While significant levels of IL-10 were
detected in the serum of LPS-treated mice, this cytokine could not be detected in the serum
of flagellin-treated mice (Figure 8B).
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FIGURE 8. Serum levels of IL-12p40-70 and IL-10 in mice treated with LPS
or flagellin.
BALB/c mice were injected iv with either flagellin (10 µg), LPS (10 µg) or an equal
volume of HBSS (0.1 ml). Blood was collected 1.5 hours later and serum levels of
IL-12p40-70 (A) or IL-10 (B) were determined by ELISA. Shown is a
representative experiment with four animals per group of two independent
experiments with similar results. Each dot represents an animal and the line
indicates the group’s mean.
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Other proinflammatory cytokines as IL-6 were also detected in flagellin-treated
mice. Of notice, TNF-α was absent from the serum of these animals (Figure 9). Several
lines of evidence indicate that TNF-α is the principal mediator in the pathogenesis of septic
shock. First, neutralizing anti-TNF-α antibodies can prevent the pulmonary failure and
death associated with administration of endotoxin or Escherichia coli in mice (147).
Second, intravenous infusion of TNF-α leads to a toxic syndrome indistinguishable from
that caused by endotoxemia and gramnegative sepsis (147-148). These observations might
indicate that the low toxicity observed by previous studies and also in our own experiments
in flagellin-treated as compared with LPS-treated mice might be due to the absence of
TNF-α in the serum of flagellin-treated animals.
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FIGURE 9. IL-6 and TNF-α blood serum levels in flagellin-treated
animals
BALB/c mice were injected iv with either flagellin (10 µg) or an equal
volume of HBSS (0.1 ml). Blood was collected 1.5 hours later and serum
levels of IL6 or TNFα were determined by ELISA. Shown is a representative
experiment with three animals per group
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IL-10 mRNA dynamics in flagellin-stimulated PEM
In order to assess if flagellin stimulation of macrophages results or not in the
induction of IL-10 mRNA we determined the IL-10 mRNA kinetics in flagellin treated
macrophages and compare them to those obtained in LPS-treated macrophages
(Figure 10).
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FIGURE 10. IL-10 mRNA dynamics in flagellin-stimulated macrophages.
PEM were cultured in media or stimulated with LPS (1 µg/ml) or flagellin (5 µg/ml) and
the cells harvested in TriZol at the indicated time points. RNA was extracted and IL-10
relative to GAPDH mRNA was determined by quantitative RT-PCR. Data shows the
ratio expressed in arbitrary units of treated versus untreated cells obtained at each of the
time points. Shown is one of three independent experiments with similar results.
In response to LPS stimulation, a rapid increase in IL-10 mRNA was observed by
3 hours, followed by a peak response at 6 hours after treatment. This induction is followed
by a progressive decline and, after 12 hours of exposure to LPS, the IL-10 mRNA levels
were back to baseline (Figure 10-white squares). The magnitude and kinetics of IL-10
mRNA were significantly different in flagellin-treated PEM. Following three hours of
incubation, only a weak induction of IL-10 mRNA was detected by RT-PCR. This initial
response was followed by a rapid decline and by 6 hours, IL-10 mRNA levels in flagellintreated PEM were equivalent to those found in untreated cells (Figure 10-black squares).
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IL-10 mRNA dynamics in bone marrow-derived macrophages
PEM are elicited using a mild inflammatory agent (thyoglicollate). Therefore they
have been exposed to maturating signals that might have affected their ability to respond to
flagellin. In other to assess this possibility we generated macrophages from bone marrow
(BM-macrophages) and exposed them to either LPS or flagellin. As shown in Figure 11
a similar pattern of IL-10 mRNA expression was observed in flagellin-treated BM-derived
macrophages as compared to PEM (black squares).
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FIGURE 11. IL-10 mRNA dynamics in flagellin stimulated BM-derived
macrophages.
(A) BM-derived macrophages were cultured in complete media and stimulated with either
LPS (1 µg/ml) or flagellin (5 µg/ml). Cells were then harvested in TriZol at the indicated
time points. RNA was extracted from these cells and IL-10 mRNA relative to GAPDH
mRNA was determined by quantitative RT-PCR. Data shows the ratio expressed in
arbitrary units of treated cells versus untreated cells obtained at each of the indicated time
points. Shown is a representative experiment of three independent experiments with
similar results.
BM-derived macrophages express TLR5 (Figure 12A). Reminiscent of our
findings with PEM (Figure 6B), no IL-10 protein was detected in the supernatants of
BM-derived macrophages stimulated with flagellin (Figure 12B). The lack of IL-10
40

production is not due to the unresponsiveness of these cells since they produce significant
levels of IL-12 p40-70 when stimulated with flagellin (Figure 12C)
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FIGURE 12. BM-derived
macrophages express TLR5
and produce IL-12p40-70 but
not IL-10 when stimulated
with flagellin.
(A) RNA from BM-derived
macrophages was analyzed for
TLR5
mRNA
expression
relative to GAPDH using
realt-time RT-PCR. (B) and (C)
BM-derived macrophages were
cultured for 24 hours with LPS
(1 µg/ml) or flagellin (5 µg/ml).
Supernatants were collected and
the levels of IL-10 and
IL-12p40-70 were measured by
ELISA. Data represent mean ±
s.d. of triplicate cultures. Shown
is a representative experiment of
two independent experiments
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Taken together, our data indicates that flagellin induces a short-lived expression of IL-10
mRNA in macrophages. The transient induction of IL-10 expression by flagellin might
not be enough to result in detectable levels of IL-10 protein production
LPS-induced IL-10 mRNA and protein are inhibited by flagellin
Several TLR ligands can be found in any microbial organism; furthermore APCs
and other immune cells express more than one TLR. Therefore during an ongoing
infection, flagellin and other TLR ligands expressed in flagellated bacteria are likely to be
recognized by cells of the immune system either simultaneously or sequentially. In order
to find whether flagellin could influence the production of IL-10 in response to other
TLR ligands, we treated PEM with flagellin and the TLR4 ligand (LPS) either
simultaneously (Figure 13) or sequentially (Figures 14 and 15). As shown in Figure 13A,
no differences in IL-10 mRNA levels were observed in peritoneal macrophages after 2
hours of exposure to either LPS alone (white squares) or LPS in the presence of flagellin
(F/LPS: black squares). However, unlike stimulation with LPS alone, IL-10 mRNA levels
declined rapidly by 4 and 6 hours of simultaneous engagement of TLR4 and TLR5. The
inhibition of IL-10 by flagellin was also reflected at the protein level. As displayed in
Figure 13B, a dose dependent inhibition of IL-10 production was observed when PEM
were treated with LPS (1 μg/ml) in the presence of increasing concentrations of flagellin.
Inhibition of IL-10 was not observed when the TLR5-deficient cell line RAW 264.7 was
treated with LPS and flagellin, indicating that flagellin-induced IL-10 inhibition in
response to LPS requires TLR5 expression (Figure 13C).
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FIGURE 13. Flagellin inhibits LPSinduced IL-10 protein and mRNA
(A) PEM were stimulated with 1 µg/ml
LPS alone (open squares) or with LPS
(1µg/ml) in the presence of 20 µg/ml
flagellin (F/LPS, black squares). Cells
were then harvested at the indicated
time points. IL-10 mRNA levels were
determined as in Figure 10. Data shows
the ratio expressed in arbitrary units of
treated cells versus untreated cells
obtained at each of the indicated time
points. Shown is a representative
experiment of two independent
experiments with similar results. (B, C)
PEM or RAW 264.7 cells were
stimulated with LPS alone (1 µg/ml) or
LPS plus increasing concentrations of
flagellin for 24 hours as indicated.
Supernatants were then collected and
the levels of IL-10 were determined by
ELISA. Data represent mean ± s.d. of
triplicate cultures. Shown is a
representative experiment of two
independent experiments with similar
results.

Pretreatment of macrophages with flagellin results in stronger inhibition of LPSinduced IL-10
Flagellin treatment decreased LPS-induced IL-10 mRNA levels at later times when
macrophages are simultaneously stimulated with flagellin and LPS. This result prompted
us to investigate how LPS induced IL-10 mRNA would behave if the cells are exposed to
flagellin before LPS stimulation (Figure 14).
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FIGURE 14. A short pretreatment with flagellin affects IL-10 and IL-12
induction in an opposite way
PEM were cultured with flagellin (5 µg/ml) or just media for the indicated time
length after which LPS (final concentration 1µg/ml) was added. Cells were
harvested 2 hours after LPS addition and the levels of IL-10 (white squares) and
IL-12 p40 (black squares) mRNA relative to GAPDH quantified using real-time
RT-PCR.
44

Figure 14 shows IL-10 (white squares) and IL-12p40 (black triangles) mRNA
after 2 hours of treatment with LPS in cells that have received or not flagellin
pretreatment. IL-10 mRNA inhibition by flagellin was substantially increased when the
cells were exposed to flagellin 3 hours before LPS treatment. Increasing the time in
contact with flagellin to 6 hours before LPS stimulation resulted in similar levels of
inhibition to those observed after 3 hours treatment.
Interestingly, IL-12p40 mRNA production by LPS was enhanced by pretreatment
with flagellin for 3 hours. However the observed enhancement was gone when flagellinpretreatment was increased to 6 hours. Treating the cells for 12 hours with flagellin prior
to LPS stimulation made the cells refractory to further stimulation with LPS (149-150).
Given these results, in our next experiments we used macrophages that have been
stimulated with flagellin for a short period of time (3 hours) before adding LPS to the
media. A profound inhibition of IL-10 mRNA expression was observed when PEM were
exposed to flagellin (5 μg/ml) for 3 hours prior to LPS stimulation (Figure 15A). In
addition decreased levels of IL-10 protein were observed in PEM pretreated with flagellin
(5μg/ml) and then stimulated with increasing concentrations of LPS (Figure 15B). In the
pretreatment setting, flagellin at a dose of 5μg/ml, which has minimal inhibitory effect
when used simultaneously with LPS (Figure 13B), displayed stronger IL-10 inhibitory
properties. Conversely, the inhibitory effect of flagellin on IL-10 production was not
observed when the TLR5-deficient cells RAW 264.7 were pretreated with flagellin
(Figure 15C).
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FIGURE 15. Inhibition of IL-10
by flagellin is enhanced by a
short pretreatment
(A) PEM were treated with 5
µg/ml flagellin (black bars) or
with media alone (white bars) for
3 hours, followed by the addition
of LPS (1µg/ml). Cells were
Media
Flagellin harvested at the indicated time
points after the addition of LPS.
IL-10 mRNA relative to GAPDH
mRNA was determined by quantitative real-time RT-PCR. Shown
is a representative experiment of
four independent experiments
with similar results. (B, C) PEM
or RAW 264.7 cells were cultured
with flagellin (5 µg/ml) or media
alone for 3 hours, followed by
stimulation with LPS (1µg/ml).
Supernatants were collected 24
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hours after LPS addition and the
Flagellin
levels of IL-10 were determined
by ELISA. Data represents mean
± s.d. of triplicate cultures. Shown
is a representative experiment of
three independent experiments.
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IL-10 inhibition by flagellin is restricted to specific TLRs
To determine whether a similar inhibitory effect over IL-10 production occurs
when PEM are exposed to TLR-ligands other than LPS, we treated PEM with flagellin
followed by stimulation with either zymosan (TLR2/6 ligand) or CpG (TLR9 ligand). As
shown in Figure 16A, treatment of PEM with increasing concentrations of zymosan
results in IL-10 production in a dose dependent manner (white bars). However, when
these cells were treated with flagellin and then zymosan, a dramatic decrease in IL-10
production was observed (Figure 16A-black bars). In contrast, such an inhibitory effect
on IL-10 protein production was not observed when PEM were pretreated with flagellin
followed by CpG (Figure 16B). In order to assess if flagellin pretreatment decreased
CpG-induced IL-10 at the mRNA but not at the protein levels we quantified the levels of
IL-10 mRNA in PEM pretreated with flagellin or media followed by CpG. In agreement
with the results obtained at the protein level, flagellin did not affect the IL-10 mRNA
levels induced by CpG in PEM (Figure 16C). To summarize, our results have unveiled a
previously unknown effect of flagellin in the negative regulation of IL-10 production in
response to specific TLR ligands.
Interestingly zymosan, flagellin and LPS engage TLRs that localize in the cellular
membrane while CpG is detected by an intracellular receptor. IL-10 production by
surface receptors but not by intracellular receptors is affected by flagellin stimulation
suggesting that receptor colocalization might be required for TLR5-mediated IL-10
repression.
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FIGURE 16. IL-10 production
by macrophages treated with
flagellin and other TLR
ligands.
PEM were cultured in media
alone (white bars) or with 5
µg/ml of flagellin (black bars) for
3
hours,
followed
by
stimulation
with
either
Zymosan (A) or CpG (B).
Supernatants were collected 24
hours later and the production
of
IL-10
protein
was
determined by ELISA. Data
represent +/- s.d. of triplicate
cultures.
Shown
is
a
representative experiment of two
independent experiments with
similar results. (C) Cells were
harvested at the indicated time
points after the addition of CpG.
IL-10 mRNA relative to
GAPDH
mRNA
was
determined by
real-time
RT-PCR.
Shown
is
a
representative experiment of two
independent experiments with
similar results.

IL-10 inhibition might depend on receptor colocalization
In unstimulated macrophages and DCs TLR5 and TLR9 have been shown to be
expressed in different cellular compartments. TLR5 localizes to the cellular membrane
(47) while TLR9 has been detected in the ER (endoplasmic reticulum) (48). Nonetheless,
TLRs present in the cellular membrane have been shown to be recruited to phagosomes
(151). In addition, phagosomes contain ER-resident proteins since ER membranes are a
source of phagocytic membranes in macrophages and other cells (152). Therefore, in the
context of phagocytosis it would be possible that TLR5 and TLR9 could localize in the
phagosomal/lysosomal compartment. To test this hypothesis we used beads as a vehicle to
introduce flagellin into the phagosomal/lysomal compartment (Figure 17).
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FIGURE
17.
Macrophages
stimulated with flagellin-coated
beads showed impair IL-10
induction by CpG
PEM were cultured with flagellin
coated beads (equivalent to 5µg/ml
protein) (black bars) or beads coated
with an irrelevant protein (OVA)
(white bars). After 3 hours cells were
washed and fresh media or media
with CpG (final concentration 0.25
µM) added. Cells were harvested at
the indicated time points after the
addition of CpG. IL-10 mRNA
relative to GAPDH mRNA was
determined by quantitative real-time
RT-PCR.
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As shown in Figure 17 CpG stimulation of macrophages that have phagocyted
flagellin-coated beads resulted in inhibition of IL-10 mRNA as compared to those that
uptook control protein (ova)-coated beads. These data could support that signaling from
the same compartment is required for TLR5 negative regulation of IL-10 induction by
other TLRs.
Flagellin treatment does not affect LPS-induced IL-10 mRNA stability
Stimulation of macrophages with LPS causes a dramatic increase in the IL-10
mRNA levels that might be due to an increase in the IL-10 gene transcription and also in
the IL-10 mRNA stability (126-127), (153). In order to determine whether suppression of
LPS-induced IL-10 by flagellin was caused by an increase in IL-10 mRNA degradation,
we treated macrophages with actinomycin D, an inhibitor of mRNA synthesis, and
followed the changes induced by flagellin in the stability of LPS-induced IL-10 mRNA.
Figure 18A shows that actinomycin D suppresses mRNA synthesis. For this control
experiment, cells were treated with LPS plus actinomycin D or LPS plus media for two
hours. Cells were then harvested and the levels of IL-10 mRNA were measured by RTPCR. Actinomycin D (5 μg/ml) completely blocked the synthesis of new mRNA (LPS +
ActD). In our next set of experiments, PEM were cultured for 3 hours with either
flagellin or media and then LPS was added. Actinomycin D was added to the cultures 2
hours after LPS treatment and cells were harvested at the indicated time points after
actinomycin D treatment. As shown in Figure 18B, an almost identical rate of IL-10
disappearance was observed; suggesting that pretreatment with flagellin does not affect
IL-10 mRNA stability in response to LPS stimulation.
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FIGURE 18. IL-10 repression by flagellin is not caused by a decrease in IL-10 mRNA
stability
(A) PEM were cultured with LPS (1 µg/ml) plus actinomycin D (5 µg/ml) or vehicle. After 2
hours treatment the cells were harvested and the IL-10 mRNA levels relative to GAPDH mRNA
were determined by RT-PCR. (B) Actinomycin D or vehicle were added to the media 2 hours after
LPS treatment of PEM that had been cultured with (black squares)or without flagellin (without
squares). Cells were harvested 2,4 and 6 hours after actinomycin D addition and the IL-10 mRNA
levels relative to GAPDH mRNA were determined by RT-PCR. Shown is a representative
experiment of two independent experiments with similar results
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Flagellin stimulation decreases ERK activation by LPS in macrophages
A general outcome upon TLR engagement is the activation of the NFκB and the
mitogen-activated protein kinase (MAPK) signaling pathways. Among the MAPKs,
several studies have linked the extracellular signal regulated kinases (ERKs) with IL-10
regulation by TLRs. These studies found that IL-10 induction by different TLRs depends
on ERK activation (154-158). In order to assess if flagellin stimulation would affect LPSinduced ERK phosphorylation we treated PEM with flagellin or media followed by LPS
stimulation. Since significant changes in the LPS-induced IL-10 mRNA levels are
detected in flagellin-treated macrophages at 2 hours stimulation with LPS (Figure 15A)
we decided to quantify ERK phosphorylation at earlier time points (30 and 60 minutes).
Interestingly, LPS-induced phosphorylated ERK 1/2 levels were significantly reduced in
flagellin-treated macrophages as compared with media-treated macrophages (Figure 19).
This result suggests that decreased ERK activation could play a role in flagellin-mediated
IL-10 inhibition.
NFκB activation plays a central role in inducing the expression of
proinflammatory mediators by TLRs.

In resting cells NFκB is sequestered in the

cytoplasm by molecules known as inhibitor of nuclear factor-κB (IκB). Phosphorylation
of IκB results in its degradation and in the release of NFκB that now can translocate to
the nucleus and activate its target genes (62). Macrophages treated with flagellin or LPS
alone showed increased IκB phosphorylation suggesting that treatment with these TLR
ligands results in NFκB activation. As seen in Figure 19, flagellin treatment in
combination with LPS did not result in decreased p-IκB levels as compared with cells
treated with LPS alone. These data suggest that the NFκB activation by LPS is not
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affected by flagellin treatment and therefore is not involved in flagellin-induced IL-10
inhibition
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FIGURE 19. Flagellin treatment decreases ERK activation by LPS in
macrophages
PEM were cultured with 5 µg/ml flagellin (F/) or just media for 3 hours (-/) followed
by the addition of 1 µg/ml LPS (/L). Cells were harvested 30 minutes and 1 hour after
LPS addition. Whole-cell lysates were obtained and subjected to SDS-PAGE
immunoblotting with the indicated antibodies. Unphosphorylated ERK 1/2 was used
as loading control. Shown is a representative experiment of two independent
experiments with similar results.
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Flagellin enhances IL-12 production in response LPS
To further confirm the data suggesting that a short pretreatment with flagellin
results in enhanced IL-12 production by LPS (Figure 14), we determined the IL-12 p40/
IL-12 p35 mRNA levels in macrophages treated with flagellin and LPS (Figure 20).
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FIGURE
20.
Flagellinstimulated PEM produce higher
levels of IL-12p35 and IL-12p40
mRNAs in response to LPS.
(A-B) PEM were cultured with 5
µg/ml flagellin (F) for three hours.
Then supernatants were removed
and media (-) was added (F/-,
white bars). In parallel, PEM were
cultured with media alone (-) for
three hours and then LPS was
added (-/LPS, gray bar). A third
group consisted of PEM pretreated
with flagellin (F) for three hours
and then stimulated with LPS
(F/LPS, black bar). Cells were
harvested at the indicated time
points after the addition of LPS
and the levels of IL-12p40 (A) and
IL-12p35 mRNA (B) relative to
GAPDH were determined by
quantitative RT-PCR. Shown is a
representative experiment of four
independent experiments with
similar results.
Statistical analysis was performed
using t-test.

Flagellin pretreatment increased the level of IL-12p40 mRNA in response to LPS
stimulation for two hours (Figure 20A, black bar-2 hours). This increase is short-lived
since at 4 hours IL-12p40 mRNA levels were back to those observed in PEM treated with
LPS alone (Figure 20A- 4 hours). In addition, an increase in IL-12p35 mRNA levels was
observed in PEM treated with flagellin and subsequently stimulated with LPS (F/LPS:
black bars) (Figure 14B). The response duration was longer than the one observed for IL12p40 mRNA induction, since enhanced levels of IL-12p35 mRNA were still observed
after 4 hours of exposure to LPS (Figure 20B-4 hours).
The biologically active form of the cytokine IL-12 is a heterodimer composed of
the IL-12 p40 and p35 proteins and known as IL-12 p70 (94). IL-12 p40 has been
reported to be produced in excess over IL-12p35 which acts as a limiting factor for IL-12
p70 production (96). Therefore, an increase in IL-12 p35 might result in elevated IL-12
p70 protein production that would not be detected using standard ELISA methods that do
not discriminate between IL-12p40 and IL-12p70 production. For this reason, we
specifically analyzed IL-12p70 production by PEM pretreated with flagellin followed by
LPS. As shown in Figure 21, when PEM are pretreated with flagellin and then exposed to
increased concentrations of LPS (black bars) they produced higher levels of IL-12p70
relative to PEM treated with LPS alone (white bars). In summary, PEM treated with
flagellin and then stimulated with LPS display enhanced expression of both IL-12p40
mRNA (Figure 20A) and IL-12p35 mRNA (Figure 20B) as well as increased production
of IL-12p70 protein (Figure 21).
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Flagellin enhances IL-12p70 production in response to CpG
To determine whether flagellin-mediated enhancement of IL-12p70 production
occurs only in response to LPS-stimulation or could also be observed in response to other
TLR ligands, PEM were treated with flagellin in combination with either zymosan or CpG.
While treatment with flagellin did not enhance IL-12p70 production in response to
zymosan that remained undetectable (data not shown), a significant increase in IL-12p70

IL-12p70 (pg/ml)

production was observed when PEM were treated with flagellin and CpG (Figure 22).
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PEM produce higher levels of
B
IL-12p70 in response to TLR9
p< 0.0001
2000
ligands.
PEM were cultured with media
1600
alone (open bar) or with flagellin 5
µg/ml (black bar) for 3 hours.
1200
Then, PEM were treated with 0.25
µM CpG. Supernatants were
800
collected after 24 hours and IL-12
p70 levels were determined by
400
ELISA. Data represent mean ± s.d.
of triplicate cultures. Shown is a
0
Media
Media/CpG
Flagellin/CpG
representative experiment of three
with similar results.
Statistical analysis used was t-test
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These results (Figure 21 and 22) indicate that ligation of TLR5 in macrophages
influences the inflammatory response of these cells to TLR4 and TLR9 ligands (LPS and
CpG) resulting in enhanced production of the proinflammatory mediator IL-12p70.
Blocking IL-10 increases IL-12p70 production by LPS-stimulated macrophages
IL-10 has been shown to act as a powerful inhibitor of IL-12 production (107-108).
Therefore, in the next experiment we assessed if blocking IL-10 signaling would enhance
IL-12p70 production by LPS-treated PEM (Figure 23).
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FIGURE 23. IL-10 blockage increases IL-12p70 production by
LPS-stimulated macrophages
Macrophages were cultured with LPS (1 µg/ml) (black squares) or
media alone (white bars) plus IL-10 blocking antibody at the indicated
concentration. After 24 hours culture the supernatants were harvested
and IL-12 p70 production quantified by ELISA.
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Incubating the cells with increasing amounts of IL-10 blocking antibody increases IL-12
p70 production in a dose dependent manner (Figure 23). This result indicates that IL-10 repression
by flagellin could be, at least in part, responsible for the increase in IL-12 p70 production observed
in macrophages treated with flagellin in combination with LPS. Nonetheless, other mechanisms
must be also playing a role since enhanced IL-12 p70 production was observed in macrophages
treated with a combination of flagellin and CpG even when on those cells IL-10 production was
not affected by flagellin stimulation (Figure 16).
Flagellin elicits CD4+ T-cell activation in a tolerogenic setting in vivo
In previous studies we have shown that APCs that produce significant levels of IL-12 in the
absence of the inhibitory cytokine IL-10 effectively prime naïve antigen-specific CD4+ T-cells
and are capable of restoring the responsiveness of tolerized CD4+ T-cells (141). This finding,
along with our data demonstrating that flagellin-treated APCs produce IL-12 but not IL-10, led us
to explore whether treatment with this TLR-ligand could overcome antigen-specific CD4+ T-cell
tolerance in vivo.

Anti-HA
CD4+T-cells

Day 0

HA-peptide

Analysis

Day +2

Day +15

FIGURE 24. High dose peptide model of antigen-specific CD4+ Tcell tolerance
(I)
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To answer this question, we followed the experimental design outlined in Figure
24. Briefly, 2.5x106 naïve CD4+ T-cells specific for a MHC class II-restricted epitope of
influenza hemagglutinin (HA) were adoptively transferred intravenously (iv) into
BALB/c mice. Twenty-four hours later, mice were given iv a tolerogenic dose of HApeptide (200 μg), a combination of HA-peptide together with flagellin (10 μg), or left
untreated. Two weeks later, all the mice were sacrificed and the splenocytes harvested.
Previous studies have shown that antigen encounter by clonotypic CD4+ T-cells in mice
treated with a high dose of their cognate antigen leads to progressive T-cell deletion (159160). Indeed, as shown in Figure 25, in those mice treated with high dose HA-peptide, we
observed a dramatic decrease in the percent of clonotypic CD4+ T-cells (0.34% in HApeptide treated mice versus 1.02% in untreated mice). Such a decrease in clonotypic Tcells was prevented however in mice treated with tolerogenic dose of HA-peptide plus
flagellin (Figure 25A). Assessment of cytokine production by clonotypic T-cells isolated
from the different experimental groups also showed important differences. While
treatment with high dose HA-peptide resulted in slight decrease in the production of IFNγ by clonotypic T-cells isolated from these mice relative to the untreated group, the
opposite outcome was observed in mice treated with a high dose of peptide together with
flagellin. Clonotypic T-cells from these mice produced higher levels of IFN-γ in response
to restimulation with cognate antigen, indicating that they have been primed in vivo in
response to an otherwise tolerogenic dose of peptide (Figure 25B)
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FIGURE 25. Flagellin elicits CD4+ T-cell activation in a tolerogenic
setting (I).
6
BALB/c mice received 2.5 x 10 anti-HA TCR+ transgenic CD4+ T cells iv
Twenty-four hours later mice were left untreated, given HA-peptide (200
µg/iv) alone or HA peptide (200 µg/iv) in combination with flagellin (10
µg/iv). Two weeks later mice were sacrificed and T cells were purified from
their spleens as described in Methods. (A) Shows two-color FACS analysis of
splenocytes from one animal in each experimental group (each consisted of
four animals). Upper right quadrant numbers represent the percentage of
double positive CD4+ T- cells. (B) Purified T-cells from untreated mice or
mice treated with high dose HA-peptide in vivo or HA-peptide plus flagellin
were restimulated with HA-peptide (12.5 µg/ml) in vitro for 48 hours.
Supernatants were collected and assayed for IFN-γ production by ELISA.
Each dot represents an animal and the bar represents the group’s average.
Shown is a representative experiment of three independent experiments with
similar results. Data is expressed as the amount of cytokine produced by 100
clonotype+ T cells/well.
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In this model of antigen-specific T-cell tolerance we have also demonstrated that
anergic anti-HA CD4+ T-cells are unable to respond to inflammatory stimuli provided by
a recombinant vaccinia virus encoding HA (vaccHA). Therefore, in our next experiment
we asked whether flagellin treatment could change this outcome and preserve
antigen-specific T-cell responsiveness to the model antigen expressed by vaccinia virus.
For this experiment we followed the esperimental design outlined in Figure 26.

Anti-HA
CD4+T-cells

Day 0

HA-peptide

Vacc-HA

Analysis

Day +2

Day +9

Day +15

Flagellin IV Day +2

FIGURE 26. High dose peptide model of antigen-specific CD4+ T cell tolerance (II)
First, antigen-specific T-cells reisolated from vaccinia HA-infected mice produced
significant levels of IL-2 in response to in vitro stimulation with cognate HA-peptide
(Figure 27, Untreated). Clonotypic T-cells from mice treated with a tolerogenic dose of
HA-peptide failed to respond to vaccHA immunization in vivo as determined by their lack
of IL-2 production in response to cognate HA-peptide (Figure 27, HA peptide). In sharp
contrast, flagellin treatment preserved the response to vaccination in this tolerogenic
setting, since clonotypic T-cells isolated from these mice produce levels of IL-2 that are
equivalent to those produced by antigen-specific T-cells from control mice (Figure 27, HA
+ flagellin).
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Summarizing, in vivo treatment with flagellin converts a tolerogenic environment
into an inflammatory one in which antigen-specific CD4+ T-cells not only are not deleted
but are efficiently activated and capable of responding to a subsequent immunization with
recombinant vaccinia encoding HA.
FIGURE 27. Flagellin elicits
CD4+ T-cell activation in a
tolerogenic setting (II).
Untreated mice, mice treated with
high dose HA peptide or mice that
60
received high dose HA-peptide
plus flagellin in vivo were
immunized with 1x10 7 pfu of
recombinant vaccinia encoding HA
40
(vaccHA) on day +9 after T-cell
adoptive transfer. Six days later
animals were sacrificed and T-cells
isolated from their spleens. Purified
20
T cells were stimulated with
HA-peptide plus fresh splenocytes
for 48 hr. Supernatants were
collected and assayed for IL-2
production by ELISA. Data
0
Untreated
HA peptide HA + Flagellin represent mean ± s.d. of triplicate
cultures from three mice in each
group.
DC differentiation in the presence of IL-10
IL-2 (pg/ml)
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Several studies have shown that DC differentiation in the presence of IL-10 results
in the development of DCs that produce high levels of IL-10 and induce T cell anergy and
regulatory T cell differentiation (143-144). DCs differentiated in these conditions have
been shown to induce tolerance (144), therefore to avoid confusion between BM-DCs
differentiated using different protocols, DCs differentiated with GM-CSF plus IL-4 will be
called just BM-DCs and those differentiated in the presence of IL-10 will be called
tolerogenic-DCs.
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Our first goal for the series of experiments described bellow, was to generate DCs
in the presence of IL-10 and evaluate their ability to present antigen. Differentiation of DCs
in the presence of the anti-inflammatory cytokine IL-10 rendered similar yield of CD11c+
cells to those obtained by standard procedures (around 90%) even when these cells are
characterized by a lower expression of this marker (Figure 28).
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FIGURE 28. CD11c expression in DCs
differentiated in the presence of IL-10
Bone marrow cells were cultured for 7
days in the presence of GM-CSF and
IL-4 (A) or GM-CSF, IL-10 and TNF-α
(B). On day 8, loosely adherent cells
were harvested by flushing the plate with
ice-cold HBSS and expression of the
dendritic cell specific marker CD11c
quantified by FACS analysis. (C) Shows
a histogram comparing the magnitude of
CD11c expression in both DC subsets
and the isotype control antibodies.
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As previously shown by others, expression of costimulatory molecules as MHCII
or B7.2 was reduced in those cells that have been differentiated in the presence of IL-10 as
compared with those differentiated following a standard protocol (Figure 29).
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FIGURE 29. Tolerogenic-DCs
express
lower
levels
of
costimulatory
molecules
than
BM-DCs
Bone marrow cells were cultured for
7 days in the presence of GM-CSF
and IL-4 (BM-DCs) (shaded area) or
GM-CSF,
IL-10
and
TNF-α
(tolerogenic-DCs) (solid line). On
day 8, loosely adherent cells were
harvested by flushing the plate with
ice-cold HBSS and expression of the
costimulatory molecules B7-2 (A)
and MHC class II (B) were quantified
by FACS analysis.

Tolerogenic-DCs induce T cell unresponsiveness in vitro.
In order to compare T cell priming by tolerogenic-DCs and BM-DCs we developed
a protocol for T cell priming and differentiation in vitro, summarized in Figure 30
BM-DCs or tolerogenic-DCs
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FIGURE 30. T cell differentiation diagram
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Briefly, naïve CD4+ T cells (CD4+ CD62L high) from HA +/- mice were cultured
with DCs and antigen (HA peptide) for 7 days. This period of time is enough to allow T
cell differentiation. After 7 days T cells were washed and transferred to a second plate were
they were restimulated with antigen and fresh splenocytes used as antigen presenting cells.
Culture of naïve CD4+ T cells with tolerogenic-DCs resulted in significantly lower levels
of IFN-γ production and proliferation relative to T cells that have been cultured with
BM-DCs (Figure 31) indicating that the antigen presenting function in tolerogenic-DCs is
impaired. Lower expression of MHCII and costimulatory molecules by tolerogenic-DCs
could account for the deficient priming of antigen specific CD4+ T cell responses.

A

FIGURE 31. T cells differentiated using
tolerogenic-DCs showed impaired
responses upon antigen restimulation
T cells were differentiated as in Figure 30
and their responses upon antigen restimulation evaluated in terms of (A) proliferation (H3 incorporation) and IFN-γ production (B).
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LPS stimulation of tolerogenic-DCs results in enhanced production of IL-10
Cytokine induction in tolerogenic-DCs by TLR ligands has not been fully
characterized but evidence in the literature suggests an increase in IL-10 production
associated with a decrease in proinflammatory cytokine production (144). In Figure 32
tolerogenic-DCs or BM-DCs were treated with LPS and the production of IL-10 or
IL-12p40-70 quantified after 24 hours treatment.
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FIGURE 32. LPS stimulation
of tolerogenic-DCs results in
enhanced production of IL-10
BM-DCs (white squares) or
tolerogenic-DCs (black squares)
were cultured in the presence of
increasing concentrations of LPS
(0.5, 1 and 2 µg/ml). After 24
hours the supernatants were
removed and IL-10 and IL-12
p40-70 quantified by ELISA

In agreement with others (165), Figure 32B shows that tolerogenic-DCs produce
much higher levels of IL-10 than BM-DCs. Nonetheless, IL-12 p40-70 production by both
DC subsets was similar (Figure 32A) suggesting that the capacity to produce IL-12p40-70
was not diminished in DCs that have been exposed to IL-10 during differentiation.
TLR5 expression is specifically enhanced in tolerogenic-DCs
The increased capacity to produce IL-10 by tolerogenic-DCs prompted us to
investigate whether they would produce this cytokine in response to flagellin. First, we
evaluated their ability to respond to flagellin stimulation by measuring TLR5 expression in
BM-DCs and tolerogenic-DCs using quantitative RT PCR (Figure 33).
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FIGURE 33. TLR5 expression is specifically enhanced in tolerogenic-DCs
BM-DCs (white bars) and tolerogenic-DCs (black bars) were obtained as
detailed in the materials and methods section. After harvesting the cells, RNA
was isolated using Trizol reagent and the levels of TLR5, TLR4 and TLR9 were
quantified by real time RT-PCR using GAPDH as an internal control. In the
graph the levels of TLR expression in tolerogenic-DCs are quantified relative to
the levels of expression in BM-DCs.
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Surprisingly, TLR5 expression was greatly enhanced in DCs differentiated in the
presence of IL-10. To assess if increased TLR expression in tolerogenic-DCs was specific
for TLR5 or also occurred with other TLRs we quantified TLR4 and TLR9 expression in
both DCs subsets. As shown in Figure 33, TLR4 and TLR9 expression levels are similar
between BM-DCs and tolerogenic-DCs suggesting that IL-10 signaling might specifically
enhance TLR5 expression in DCs.
IL-10 treatment of BM-DCs does not result in TLR5 upregulation
DCs differentiated in the presence of IL-10 display higher levels of TLR5
expression than regular BM-DCs. To test whether a similar effect would occur when the
DCs are already differentiated, we cultured BM-DCs in media alone or supplemented with
IL-10. DCs were harvested 24 hours after treatment and TLR5 mRNA expression analyzed
using quantitative RT-PCR (Figure 34).

TLR5 mRNA

FIGURE 34. IL-10 treatment of
BM-DCs does not result in TLR5
upregulation
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TLR5 expression levels were virtually identical in DCs treated with IL-10 or those
treated with media suggesting that TLR5 expression is not enhanced by IL-10 in DCs that
are completely differentiated.
Flagellin stimulation of tolerogenic-DCs results in enhanced production of IL-12p4070 in the absence of IL-10
Tolerogenic-DCs express higher levels of TLR5 mRNA than BM-DCs. In
agreement flagellin-treated tolerogenic DCs produced much higher levels of IL-12p40-70
than flagellin-treated BM-DCs (Figure 35A).
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FIGURE 35. Flagellin stimulation of tolerogenic-DCs results in
enhanced production of IL12p40-70 in the absence of IL-10
BM-DCs and tolerogenic-DCs
were differentiated as described in
the methods section. DCs were
treated with flagellin (at the
indicated concentrations 2.5, 5 and
10 µg/ml). After 24 hours culture
the supernatants were harvested
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Flagellin-stimulated DCs, both BM and tolerogenic, did not produce IL-10. IL-10
production by tolerogenic-DCs plays a fundamental role in regulatory T cell
differentiation and inhibition of antigen-specific T cells (38) (144). Therefore, regulatory
T cell differentiation and inhibition of antigen-specific T cells should not occur when
tolerogenic-DCs are activated with flagellin since there is no production of IL-10.
LPS-treated tolerogenic-DCs but not flagellin-treated tolerogenic-DCs induce T cells
that produce high levels of IL-10
The differences in cytokine production encountered among BM-DCs and
tolerogenic-DCs prompted us to investigate how they could affect CD4+ T cell priming
and differentiation. Dendritic cell maturation and T cell priming and restimulation were
carried out as detailed in Figure 30. Briefly, BM-DCs or tolerogenic-DCs were cultured
for 24 hours in the presence of LPS, flagellin or just media. At this time supernatants
were collected and the cells were washed before adding fresh media, antigen and naïve
antigen-specific transgenic T cells. Antigen restimulation of T cells that have been
differentiated in the presence of BM-DCs resulted in production of IFN-γ, IL-10 and IL4. Effector T cells with a Th1 phenotype produce IFN-γ while IL-10 and IL-4 are
produced by Th2 cells. Therefore, our data suggest that Th1 as well as Th2 cells are
obtained when the APCs used are LPS- or flagellin-matured BM-DCs (Figure 36)
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FIGURE 36. T cells cultured
with BM-DCs produce Th1 and
Th2 cytokines
BM-DCs were matured with LPS
(1µg/ml) or flagellin (5µg/ml) and
used to prime naïve CD4+ T cells as
indicated in Figure 30.
Supernatants were collected after
48 hours of T cell restimulation and
analyzed by ELISA to detect IFN-γ,
IL-4 or IL-10 production.

Interestingly, antigen presentation by LPS-activated tolerogenic-DCs resulted in
the differentiation of T cells that produce IFN-γ, very low levels of IL-4 and high levels of
IL-10 (Figure 37).
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FIGURE 37. LPS-treated but not
flagellin-treated tolerogenic-DCs
induce T cells that produce high
levels of IL-10
BM-DCs or tolerogenic-DCs were
matured with LPS (1µg/ml) or
flagellin (5µg/ml) and used to
prime naïve CD4+ T cells as
indicated in Figure 30.
Supernatants were collected after
48 hours of T cell restimulation and
analyzed by ELISA to detect
IFN-γ, IL-4 or IL-10 production.

On the contrary, T cells that encounter antigen in flagellin-activated tolerogenicDCs are primed to produce IFN-γ but not IL-10 or IL-4. Taken together, our data
indicates that antigen presentation by LPS-matured tolerogenic-DCs results in the
differentiation of T cells with the potential to suppress the immune response as they
produce high levels of IL-10. This outcome was not observed when T cells were primed
with flagellin-matured tolerogenic-DCs as T cells differentiated this way seem to have a
typical Th1 phenotype.
Flagellin-expressing B78-H1 cells induce IL-12p40-70 production by PEM
As shown by our data and by others flagellin might function as an adjuvant to
induce inflammation in tolerogenic environments as the gut (79), lungs (83) and of
important relevance for our studies in the tumor microenvironment. A good strategy to
administer flagellin with a therapeutic purpose would be flagellin-expressing tumor cells.
Using these cells as a vaccine would ensure a continuous release of flagellin (as long as
the cells would live inside the host). Furthermore, the flagellin produced by these cells
would be free of bacterial products such as LPS that are highly toxic. To explore this
possibility, we constructed a flagellin-expressing cell using the murine melanoma cell
line B78-H1. This cell line does not express MHC class I antigens or class II molecules
(163) so it does not raise strong alloresponses against the MHC class antigens. A strong
alloresponse would divert the immune system from the antigens of therapeutic interest,
and it may also rapidly eliminate the flagellin-expressing cell from the host. We
transfected B78-H1 cells with a construct expressing the fliC gene from S.typhimurium as
described in the methods section. Figure 38A shows that flagellin production can be
detected in fliC transfected cells using a monoclonal antibody. Furthermore lysates from
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fliC expressing cells induce IL-12p40-70 production by PEM more than twice as
effectively as the wild-type, untransfected cell (Figure 38B).
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FIGURE 38. Flagellin-expressing cells stimulate production of
IL-12p40-70 by PEM
(A) shows the production of flagellin by B78-H1cells transfected with a
construct expressing the fliC gene from S.typhimurium as assessed by
western blot using a monoclonal antibody against flagellin. (B) shows the
production of ILp40-p70 cytokine by PEM upon 24 hours of treatment
with lysates from B78-H1cells transfected (FLAG) or untransfected (WT)
with the fliC expressing construct. HBSS shows the results from
vehicle-treated PEMs.
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These results provide the basis for the future development of a tumor-cell based
vaccine to be used first in experimental models (to assess efficacy and side effects) and
ultimately as an immunotherapeutic strategy to treat cancer patients.
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DISCUSSION

In this study we found that flagellin, the TLR5 ligand does not induce IL-10
protein production either in vitro or in vivo. This occurs in contrast to other TLR ligands
tested by us and others that induced production of this anti-inflammatory cytokine.
Therefore, our results unveil a distinctive feature of flagellin relative to other TLR
ligands. In addition, flagellin modifies the response elicited by specific TLR ligands by
inhibiting IL-10 and/or increasing IL-12p70 production in macrophages.
Immune cells specifically macrophages and dendritic cells display a broad
repertoire of TLRs. Furthermore, different TLR ligands (PAMPs) are often expressed
within one microorganism. These features suggest that pathogen recognition in vivo
involves more than one TLR and imply that the final cellular output will arise from the
combination of several specific responses. Combined activation of APCs with different
PAMPs has shown that specific TLRs synergize resulting in increased production of
specific cytokines, mainly IL-12p70 and IL-23 (164-165). The mechanism by which
stimulation with selected TLR pairs results in increase induction of certain genes remains
to be established. One possibility could be that this increase is due to the activation of a
novel signaling pathway/s not activated by engagement of a single TLR. Other
explanation would be that more sustained signaling occurs when TLRs act in
combination.
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Making the portrayal of pathogen recognition even more complex certain TLRs
(TLRs 1, 2, 4, 5 and 6) are present on the cell surface while others (TLRs 3, 7, 8 and 9)
are restricted to intracellular compartments (47-48). Recognition of PAMPs by TLRs in
different cellular compartments probably affects the dynamics of engagement of the
different ligands resulting in stimulation of surface receptors earlier than intracellular
receptors. In summary, detection of microorganisms by APCs probably involves
activation of several TLRs that will occur simultaneously of sequentially depending on
their cellular location
Little is known whether signaling through a TLR may result in the suppression of
a specific cytokine or signaling pathway. To our knowledge, this work represents the first
evidence that flagellin specifically suppresses IL-10 production by macrophages in
response to other TLR ligands. IL-10 inhibition by flagellin does not affect all TLR
ligands and seems to be rather selective. Our results show that flagellin’s engagement to
the membrane receptor TLR5 decreases IL-10 production in response to ligands whose
receptors are also in the cellular membrane such as TLR4 or TLR2/6 (47). In contrast,
flagellin does not decrease IL-10 production in response to a ligand (CpG) that binds to
an intracellular receptor (TLR9) (48). These findings suggest that some degree of TLR
colocalization might be needed for flagellin-mediated IL-10 suppression. Also our data
showing that CpG-induced IL-10 production is dramatically reduced in macrophages
treated with flagellin-coated beads as compared to those treated with control beads
provide some support to this possibility.
After ligand binding, TLRs dimerize and recruit TIR-containing adaptor
molecules to the TIR domain of the TLR (62). Although TLRs have been fundamentally
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described to work as homodimers, the existence of TLR heterodimers has also been
reported (46). TLR2 has been shown to interact with TLR1 and TLR6 to form
heterodimers that play an important role in the recognition of bacterial and yeast wall
components (166). Recently, TLR5 has been shown to dimerize with TLR4 in flagellintreated macrophages (167). If TLR5 is able to form heterodimers with TLRs that colocalize with it, then specific adaptor molecules recruited to the TLR5 intracellular
domain might influence their responses. However, if TLR colocalization and/or
dimerization with TLR5 are required for IL-10 inhibition in response to flagellin remains
undetermined.
The mechanism(s) by which flagellin inhibits IL-10 production are not elucidated
yet. However, the finding that flagellin-treated macrophages display a transient and shortlived expression of IL-10 mRNA along with the decrease in IL-10 mRNA observed when
macrophages are treated with flagellin and LPS suggest that the suppression occurs at the
IL-10 gene transcriptional level and/or IL-10 mRNA stability. We did not find
differences in the stability of IL-10mRNA in macrophages treated with LPS alone or with
LPS plus flagellin, what might indicate that the mechanism of suppression operates at the
transcriptional level of the IL-10 gene.
The use of specific MAPKs inhibitors and studies in mice deficient in MAPK
phosphatases have shown significant alterations on the cytokine profile induced by
different TLRs (168-169) indicating that MAPKs activity regulates TLR-induced
cytokine production. ERK, a MAPK family member, have been shown to play an
important role in the induction of IL-10 by LPS (154) and other TLR ligands (155-157)
but not in the production of other cytokines such as IL-12 (158). Recent evidence
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indicates that ERK might be involved in chromatin remodeling of the IL-10 promoter in
macrophages in order to allow binding of transcription factors and gene expression (126).
In our study we report that ERK activation by LPS is significantly impaired in flagellintreated macrophages. These data suggests that flagellin might inhibit IL-10 production
through impairing ERK activation by other TLR ligands. Nonetheless, further
experiments need to be done in order to confirm the role of the ERK signaling pathway
and the potential contribution of other pathways. Furthermore, LPS-induced
phosphorylation of IκB was not altered in flagellin-treated macrophages suggesting that
the NFκB pathway is not involved in the negative regulation of IL-10 observed in
flagellin-treated macrophages. Since NFkB is a master regulator of TLR mediated
cytokine induction, our data indicating that activation of this pathway by LPS is not
affected in flagellin-treated macrophages supports that TLR5 engagement is not affecting
the global immune response elicited by other TLRs but targeting specific pathways.
We observed that flagellin enhances the production of IL-12p70 by macrophages
in response to other TLR ligands such as LPS or CpG. Given the previous demonstration
(107-108) (and also in our data) that IL-10 is a powerful inhibitor of IL-12p70
production, one possible explanation for our findings is that flagellin enhances IL-12p70
by inhibiting IL-10.

However, this assumption might not be the only explanation.

Treatment of macrophages with flagellin and CpG resulted in increased IL-12p70
production, but it was not accompanied by inhibition of IL-10. Therefore, the inhibitory
effect of flagellin on IL-10 and its ability to enhance IL-12p70 production might be
independent from each other and mediated by different mechanisms.
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Overall our findings suggest a potential scenario in which the ability of flagellin
to inhibit IL-10 could facilitate the induction of inflammatory responses by flagellated
bacteria. This effect would be particularly important in organs such as colon and lungs. In
these organs immune responses are tightly regulated mainly by the production of IL-10 to
avoid inflammation caused by commensal microorganisms (170-171) (88). Furthermore,
flagellin has been shown to play a central role in inducing inflammatory responses in
lungs and gut (80) (83) (172). Our data support that in the absence of flagellin, IL-10
would be produced in response to other TLR ligands such as LPS that is also expressed
by flagellated bacteria. In this scenario, it is likely that the inhibitory effects of IL-10
would prevail and lead to minimum or none inflammatory response. Conversely, in the
presence of flagellin and its IL-10 inhibitory effects, proinflammatory pathways (i.e. IL12) triggered by flagellin itself or other TLR-ligands would unleash stronger
inflammatory responses. Interestingly, enhanced inflammation might favor systemic
dissemination of flagellated bacteria (173). This concept is supported by recent studies in
mice with genetic disruption of TLR5 (79). In these mice, it was predicted that if the
main effect of flagellin’s recognition by TLR5 is to induce host’s protective
inflammatory responses then the absence of TLR5 would lead to increased susceptibility
to infection by flagellated microorganisms. At odds with this prediction, TLR5 -/- mice
were found to be less susceptible to systemic infection following oral challenge with
Salmonella typhimurium (79). Given our results, it is possible that in the absence of
flagellin-TLR5 interaction, IL-10 would continue to be produced in response to other
TLR ligands. In this case, resistance rather than susceptibility will be the outcome due to
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the inability of the bacteria to induce inflammation, not as a protective mechanism but as
a mechanism to facilitate its systemic dissemination.
Therefore, for the first time our studies show the effect of a TLR ligand inhibiting
the production of a specific cytokine. Furthermore, the observation that flagellin
specifically suppresses IL-10 production in response to selected TLR ligands provides a
potential explanation to how TLR5 might shape the inflammatory responses elicited by
flagellated pathogens.
Studies coming from Groux’s group (144) among others have shown that
differentiation of bone marrow derived DCs in the presence of IL-10 results in cells with
increased ability to produce IL-10. These cells (tolerogenic-DCs) in our hands responded
in a similar way producing much higher levels of IL-10 than regular BM-DCs upon LPS
stimulation. As observed before in vivo and also in macrophages, flagellin treatment of
BM-DCs or tolerogenic-DCs did not result in IL-10 protein production. Surprisingly,
flagellin-treatment of tolerogenic-DCs resulted in much higher levels of IL-12 p40-70
production than treatment of BM-DCs. One possible explanation for this result could
come from the differences in TLR5 expression among these DC subsets, as TLR5 mRNA
was much more abundant in tolerogenic-DCs than in BM-DCs. Interestingly, TLR5
expression might be specifically enhanced in tolerogenic-DCs since a similar increase in
expression was not observed in other TLRs such as TLR4 or TLR9. Based on the fact
that the major difference between both subsets has been the exposure or not to IL-10, we
explored the possibility that IL-10 treatment of DCs would result in increase expression
of TLR5 mRNA. In our experiments treatment of differentiated BM-DCs with IL-10 did
not induce any changes in TLR5 expression. This result indicate that IL-10 might
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enhance TLR5 expression in non-differentiated cells but not in fully differentiated DCs or
perhaps a longer exposure to IL-10 might be needed.
IL-10 production by APCs has been shown to induce differentiation of regulatory
T cells that produce high levels of IL-10 and limit inflammation (38). Based on this
evidence we could hypothesize that antigen presentation by flagellin-matured
tolerogenic-DCs would not result in regulatory T cell differentiation. In order to verify
this hypothesis we decided to differentiate naïve CD4+ T cells in vitro using tolerogenicDCs treated with flagellin or LPS and analyze their responses upon restimulation. Naïve
CD4+ T cells primed with flagellin or LPS-activated BM-DCs produced IFN-γ, IL-4 and
IL-10. IFN-γ is a hallmark of Th1 differentiation while IL-4 in combination with IL-10 is
produced by Th2 cells. The presence of these cytokines might indicate that Th1 and Th2
cells are induced by activated BM-DCs. T cells differentiated by tolerogenic-DCs showed
a different phenotype when the DCs were treated with LPS or flagellin. LPS-treated
tolerogenic-DCs induced T cells that produced IFN-γ, IL-10 and very low levels of IL-4.
Differentiation of T cells with this same phenotype has already been described by
Roncarolo’s group (161) when antigen presentation occurred in the presence of IL-10. In
their study in order to assess if T cells differentiated in the presence of IL-10 had a
regulatory/suppressor phenotype they explored the ability of these cells to block
inflammatory responses using an inflammatory bowel disease model (IBD). In this model
transfer of CD45RBhigh (naïve) CD4+ T cells into SCID mice, mice that lack T and B
cells, induces the development of IBD that results in colitis and weight lost. Cotransfer of
IL-10 producing T cells together with CD45RB high CD4+T cells prevented colitis
development and weight lost indicating that T cells differentiated in the presence of IL-10
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display regulatory properties. Due to their regulatory properties IL-10 producing T cells
are commonly denominated IL-10 secreting type 1 regulatory T cells (Tr1) (38). Tr1
differentiation might be abrogated when flagellin-treated tolerogenic-DCs act as APCs
since T cells differentiated in these conditions did not produce IL-10 upon restimulation.
T cells differentiated with flagellin-treated tolerogenic-DCs produced IFN-γ but very low
levels of IL-4 and IL-10 suggesting that the dominant response elicited has a Th1
character.
In summary, our results might indicate that antigen presentation by tolerogenicDCs activated with LPS results in naïve T cell differentiation into Tr1 cells meanwhile
flagellin-treated tolerogenic-DCs induce Th1 differentiation. Tr1 differentiation has been
shown to be dependent on IL-10 (174) that seems to act on the APC and not directly over
the T cell (119-121) (175). This evidence suggests that the differences in T cell
differentiation between flagellin-treated and LPS-treated tolerogenic-DCs might be
mainly due to the production or not of IL-10 by the APC. Our data supports that the use
of flagellin or other TLR5 agonists as adjuvant in situations associated with the presence
of high levels of IL-10 would be specially indicated. In contrast the use of other TLR
ligands could result in enhanced suppression of immune responses through the expansion
of T cells with a regulatory phenotype.
IL-10 production can be detected at steady conditions in gut and lungs (170) (176)
where it plays a fundamental role in the prevention of anti-microbial responses (135).
Interestingly, analysis of the TLR5 expression levels in different murine tissues have
found the highest expression in the gut (79) an evidence that supports
suggesting that exposure to IL-10 increases TLR5 expression.
84

our data

IL-10 signaling in the mucosa is likely to affect DCs in a similar way as seen in
our in vitro experiments. In fact DCs from the gut but not from the spleen produce high
levels of IL-10 upon stimulation with CD40 and microbial products (88). A similar
phenomenon might also be occurring in the lungs, since pulmonary DCs produce IL-10
and have been shown to induce Tr1 development and antigen specific T cell tolerance
(171).
Furthermore, IL-10 has been also detected in many tumors produced by tumor
cells or immune cells recruited to the tumor site (121). The presence of IL-10 in the
tumor environment has been linked with the generation of regulatory T cells (38).
Furthermore, in a recent study exploring the phenotype of tumor infiltrating DCs (TIDC)
using different carcinoma models (mammary, liver lung and colon) these cells were
characterized as having low expression levels of costimulatory molecules (CD86 and
CD40) and hyporesponsiveness to maturating stimuli. Interestingly, in order to induce
maturation of TIDC using CpG (TLR9 ligand) in vivo, CpG should be administered along
with IL-10 blocking antibodies bringing even more evidence of the suppressive role of
IL-10 on TIDCs (177). This evidence points towards a similar phenotype between TIDCs
and tolerogenic-DCs as IL-10 might be acting as the shaping agent in both situations.
A question that remains to be answered in order to use TLR5 agonists to activate
TIDCs would be if the degree of differentiation at which TIDCs are exposed to IL-10
could make a difference in their ability to express TLR5. Our data suggest that IL-10
might enhance TLR5 expression in DCs going through the differentiation proccess but
not in those that are fully differentiated. Nonetheless, DC precursors circulate in the
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blood and they have been shown to be recruited to the tumor environment (178) where
exposure to IL-10 might result in increase of TLR5 expression .
In summary, our study supports that stimulation of TLR5 might play an important
role in counteracting the anti-inflammatory effects of IL-10. TLR5 engagement limits the
production of IL-10 by innate immune cells. Furthermore it abrogates the differentiation
of IL-10 producing T cells that otherwise dominate the immune response in IL-10 rich
environments. Further studies will explore the flagellin-based vaccine we have created in
our laboratory. The finding that flagellin can prime T cell responses in tolerogenic
situations supports the use of this novel strategy to overcome tolerance to tumor antigens,
a barrier that we need to remove if we want to effectively harness antitumor immune
responses
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